




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/00, 38/04, C07H 21/02, C07K 16/00, C12N 1/20, 5/00, 15/00		A1	(11) International Publication Number: WO 97/47314
			(43) International Publication Date: 18 December 1997 (18.12.97)
(21) International Application Number: PCT/US97/09760		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 10 June 1997 (10.06.97)		<p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(30) Priority Data: 60/019,495 10 June 1996 (10.06.96) US			
(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, Mail Drop TPC-8, La Jolla, CA 92037 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MADISON, Edwin, L. [US/US]; 615 Stratford Court, No. 3, Del Mar, CA 92014 (US). KE, Song-Hua [CN/US]; 7693 Palmilla Drive #2306, San Diego, CA 92122 (US).			
(74) Agents: OLSON, Ame, M.; Olson & Hierl, Ltd., 36th floor, 20 North Wacker Drive, Chicago, IL 60606 (US) et al.			

(54) Title: USE OF SUBSTRATE SUBTRACTION LIBRARIES TO DISTINGUISH ENZYME SPECIFICITIES



(57) Abstract

The invention provides substrate subtraction libraries and methods of using substrate subtraction libraries to identify highly selective substrates for enzymes which use peptides as substrates. In one embodiment, substrates for proteases such as t-PA and u-PA have been identified whose relative reactivities towards the two enzymes vary by a factor of more than 9000. The substrates identified by the present invention are useful for the construction of highly selective enzyme inhibitors.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF SUBSTRATE SUBTRACTION LIBRARIES TO DISTINGUISH ENZYME SPECIFICITIES

Reference to Related Application

5 This application claims the benefit of U.S. Provisional Application S.N. 60/019,495, filed June 10, 1996, which is incorporated by reference, as are all references cited herein.

Governmental Rights

10 This invention was made with governmental support from the United States Government, National Institutes of Health, Grants HL52475 and HL31950; the United States Government has certain rights in the invention.

Field of the Invention

15 The invention relates to methods for elucidating specificity differences between closely related enzymes and making enzyme inhibitors based on those differences.

Background of the Invention

20 The chymotrypsin family of serine proteases has evolved to include members with intimately related substrate specificities (Perona, J.J. & Craik, C.S., Structural basis of substrate specificity in the serine proteases, Protein Science 4: 337-360, 1995). Two of these enzymes, t-PA and u-PA, were chosen to test the hypothesis that small molecule libraries could be used to identify substrates that discriminate between closely related enzymes. These two proteases possess an extremely high degree of structural similarity (Spraggon G, Phillips C, Nowak UK, et al. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator, Structure 3:681-691, 1995), share the same primary physiological substrate (plasminogen) and inhibitors (plasminogen activator inhibitor types 1 and 2), exhibit remarkably stringent substrate specificity, and play key roles in critical biological processes. Plasminogen activator inhibitors are examples of the class of molecules known as serpins (serine protease inhibitors) (Lawrence, D.A. and Ginsburg, D., in Molecular

25
30

Basis of Thrombosis and Hemostasis, K. A. High, H. R. Roberts, Eds., Marcel Dekker, New York, 1995, pp. 517-543).

In general, proteases and their inhibitors, such as serine proteases and serpins, are involved in numerous biological processes in addition to fibrinolysis, such as ovulation, fertilization, embryogenesis, angiogenesis, infection and inflammation. See, generally, Katunuma, N., et al., editors, Biological Functions of Proteases and Inhibitors, Karger, Tokyo, 1994; Troll, W., and Kennedy, A.R., editors, Protease Inhibitors as Cancer Chemopreventive Agents, Plenum Press, New York, 1993; Gettins, P.G.W., et al., editors, Serpins: Structure, Function and Biology, Chapman and Hall, New York, 1996; Sandler, M., and Smith, H.J., editors, Design of Enzyme Inhibitors as Drugs, Oxford University Press, New York, 1989). One particularly important use of protease inhibitors is in the treatment of HIV infection and AIDS (Huff, J.R., and Darke, P.L., Inhibition of HIV protease: A strategy to the treatment of AIDS, in Mohan, P., and Baba, M., editors, Anti-AIDS Drug Development, Harwood Academic Publishers, Chur, 1995)

Local activation and aggregation of platelets, followed by initiation of the blood coagulation cascade (collectively part of what is referred to as the hemostatic system), assure that a fibrin clot will form rapidly in response to vascular injury (Roberts, H. R., and Tabares, A. H. (1995) in Molecular Basis of Thrombosis and Hemostasis, K. A. High, H. R. Roberts, Eds., Marcel Dekker, New York, N.Y., 1995, pp. 35-50). The presence of this clot, however, must be transient if the damaged tissue is to be remodeled and normal blood flow restored. The fibrinolytic system, which accomplishes the enzymatic degradation of fibrin, is therefore an essential component of the hemostatic system. The ultimate product of the fibrinolytic system is plasmin, a chymotrypsin family enzyme with relatively broad, trypsin-like primary specificity that is directly responsible for the efficient degradation of a fibrin clot (Castellino, F. J. (1995) in Molecular Basis of Thrombosis and Hemostasis, K. A. High, H. R. Roberts, Eds., Marcel Dekker, New York, 1995, pp. 495-515). Production of this mature

proteolytic enzyme from the inactive precursor, or zymogen, plasminogen is the rate limiting step in the fibrinolytic cascade (Collen, D., and Lijnen, H. R. (1991) *Blood* 78, 3114-3124). Catalysis of this key regulatory reaction is tightly controlled in vivo and is mediated by two enzymes present in human plasma,

5 u-PA and t-PA.

u-PA and t-PA are very closely related members of the chymotrypsin gene family. These two proteases possess extremely high structural similarity (Spraggon, G., et al., (1995) Structure 3: 681-691; Lamba, B., et al., (1996) J. Mol. Biol. 258: 117-135), share the same primary physiological

10 substrate (plasminogen) and inhibitor (plasminogen activator inhibitor type 1, PAI-1) (Lawrence and Ginsburg, 1995), and, unlike plasmin, exhibit remarkably stringent substrate specificity.

In spite of their striking similarities, the physiological roles of t-PA and u-PA are distinct (Carmeliet, P., et al. (1994) Nature 368: 419-424;

15 Carmeliet, P., and Collen, D. (1996) Fibrinolysis 10: 195-213). Many studies (5, 6, 12-18) suggest selective inhibition of either enzyme should have beneficial therapeutic effects. Mice lacking t-PA, for example, are resistant to specific excitotoxins which cause extensive neurodegeneration in wild type mice, and mice lacking u-PA exhibit defects in the proliferation and/or migration of smooth

20 muscle cells in a model of restenosis following vascular injury.

Either increased levels of protease inhibitors, such as PAI-1, or decreased levels may be associated with diseases. Increased levels of PAI-1 in the circulation are associated with thrombotic disease, including myocardial infarction and deep vein thrombosis, and reduced post-operative fibrinolytic activity

25 (Lawrence and Ginsburg (1995) page 526). Conditions in which completely or partially reduced levels of PAI-1 are found include bleeding conditions (Schleef, R.R., et al., J. Clin. Invest. 83: 1747-1752 (1989); Fay, W.P., et al, N. Eng. J. Med. 327: 1729-1733 (1992); Liu, Y.-X., et al., Eur. J. Biochem. 195: 54-555, 1991).

A large body of experimental evidence from studies involving both model systems and human patients suggests that u-PA may play an important role in tumor biology and provides a compelling rationale to pursue the development of u-PA inhibitors. For example, anti-u-PA antibodies inhibit metastasis of HEP3
5 human carcinoma cells to chick embryo lymph nodes, heart, and lung (Ossowski, L., and Reich, E. (1983) Cell 35: 611-619), and similar studies demonstrated that these antibodies inhibit lung metastasis in mice following injection of B16 melanoma cells into the tail vein (Hearing, V. J., et al., (1988) Cancer Res. 48: 1270-1278). Anti-u-PA antibodies also inhibit both local invasiveness and lung
10 metastasis in nude mice bearing subcutaneous MDA-MB-231 breast carcinoma tumors. In addition, a recent study indicated that u-PA deficient mice are resistant to the induction and/or progression of several tumor types in a two stage, chemical carcinogenesis model. Finally, high levels of tumor-associated u-PA correlate strongly with both a shortened disease-free interval and poor survival in
15 several different human cancers (Duffy, M. J., et al., (1988) Cancer 62: 531-533; Janicke, F., et al., (1990) Fibrinolysis 4: 69-78; Duffy, M. J. (1993) Fibrinolysis 7: 295-302).

Because mice lacking either u-PA or t-PA do not develop thrombotic disorders, selective inhibition of either of these two enzymes seems
20 unlikely to create thrombotic complications in vivo. On the other hand, mice lacking both u-PA and t-PA suffer severe thrombosis in many organs and tissues, resulting in a significantly reduced life expectancy. Nonselective inhibition of these two enzymes, therefore, seems almost certain to produce catastrophic consequences in the clinical setting. Consequently, significant interest exists in the
25 development of inhibitors that are stringently specific for either t-PA or u-PA, which are expected to facilitate a detailed investigation of the precise roles of the two enzymes in several important pathological processes and may aid the development of novel therapeutic agents to combat these processes. Rational design of these selective inhibitors is greatly complicated, however, by the
30 absence of obvious "lead compounds"; both their primary physiological substrate

and inhibitors fail to discriminate between the two closely related proteases.

Combinatorial libraries provide a convenient means for screening a very large number of compounds. In general, combinatorial libraries provide a large number (10^4 - 10^8) of variants of small molecules such as peptides (Lam, K.S., Synthetic peptide libraries, in Meyers, R.A., Molecular Biology and Biotechnology. A Comprehensive Desk Reference, VCH Publishers, New York, 1995, pages 880-883). Combinatorial peptide libraries are large collections of different peptides, with many different possible combinations of amino acids joined together. The length of the peptides in the library can be chosen to suit the particular application.

The different molecules in a combinatorial library can be provided with a tag, such as an epitope recognized by an antibody, that may be used for identification and manipulation. Libraries in general can be constructed by synthesis of the different molecules on a substrate, or by a biological method, generally involving bacteriophages and bacteria.

Substrate bacteriophage display libraries have been used to elucidate optimal sub-site occupancy for substrates of t-PA and to isolate peptide substrates that were cleaved as much as 5300 times more efficiently by t-PA than peptides which contained the primary sequence of the actual target site present in plasminogen (Ding, C., et al., 1995). These selected substrates, however, were also efficiently cleaved by u-PA and therefore showed less than an order of magnitude preference for cleavage by t-PA compared to u-PA.

What is needed is a method for identifying substrates that show between about 10 fold to about 1,000 fold selectivity for one enzyme over another.

Summary of the Invention

The rational design of small molecule inhibitors as therapeutic agents is often complicated by the need to discriminate between binding to closely related enzymes. Appropriate selections of substrate phage can achieve this discrimination. Substrate subtraction libraries of the present invention provide

substrates that can distinguish between any two distinct proteases. Multiple proteases can be used in the subtraction step to achieve even greater specificity. Moreover, both substrate and substrate subtraction libraries can be prepared as described herein for any enzymes that can use peptides or proteins as substrates.

5 The present invention creates substrate subtraction libraries that are useful in the identification of highly selective substrates for specific proteins and enzymes. The present invention is particularly useful in the identification of highly selective substrates for closely-related enzymes. Indeed, it is possible to prepare substrate subtraction libraries for any enzymes that use peptides or
10 proteins as substrates. These techniques can be easily adapted to protein kinases, for example, by using antibodies against phosphoserine, phosphothreonine, or phosphotyrosine during the selection of substrate phage. Consequently, the construction and characterization of substrate and substrate subtraction libraries make substantial contributions to the rational design of highly specific, small
15 molecule inhibitors of selected enzymes, a problem of paramount importance during the development of new therapeutic agents, and to provide key insights into the molecular determinants of specificity for a variety of important enzymes.

 In one embodiment, the present invention provides a method for identifying the amino acid sequence of a peptide that is preferentially a substrate
20 for a second enzyme. A combinatorial library having components that present corresponding peptides having random amino acid sequences of a chosen length is provided. The components of the combinatorial library are contacted with the first enzyme and the library separated into two portions, one that has peptides that were modified by the first enzyme and one that has peptides that were not.
25 One or both portions of combinatorial library are contacted with the second enzyme, and the components of the combinatorial library that present corresponding peptides that were modified by contact with the one enzyme but not substantially modified by the other enzyme are identified. The sequences of the corresponding peptides that were modified by the one enzyme can then be
30 determined. The process described is called "substrate subtraction screening"

and the combinatorial libraries produced are called "substrate subtraction libraries." The first enzyme and second enzyme are generally in the same broad class of enzymes, e.g., proteases, kinases, phosphatases, and the like. A suitable combinatorial library is a bacteriophage display library.

5 Another embodiment is a compound comprising the amino acid sequence determined by the method of substrate subtraction screening described above. Such compounds are useful as enzyme inhibitors.

Stringently specific small molecule inhibitors can not only be used to assess the individual roles of t-PA and u-PA during a wide variety of
10 biological and pathological processes but also can provide important therapeutic benefits. Selective inhibition of u-PA can antagonize invasion, metastasis, and angiogenesis of specific tumors (Danø K., et al., Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985;44:139-266; Min, H.Y., et al., Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in
15 syngeneic mice. Cancer Res. (1996);in press; Ossowski, L., Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 1988;52:321-328) as well as vascular re-stenosis following invasive procedures such as angioplasty (Carmeliet P, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature
20 1994;368:419-424). Selective inhibition of t-PA can prevent specific types of neural degeneration (Strickland DK. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995;377:340-344).

In preferred embodiments, the sequence determined by the method
25 of substrate subtraction screening is incorporated in the construction of recombinant protease inhibitors, such as variants of PAI-1. In therapeutic embodiments, recombinant protease inhibitors, such as variants of PAI-1 are administered to a patient in an amount from about 0.003 to about 20 micrograms per kilogram body weight per day.

In another embodiment, antibodies to peptides identified using substrate subtraction libraries are also useful as an assay kit and method for detecting the level of active protease inhibitors. The antibodies may be used to assay the level of protease inhibitors, such as PAI-1, in a patient. The level of protease inhibitors, such as PAI-1, in a patient is a disease marker that is useful for predicting the development of a condition, identifying patients with the condition, predicting outcome of the condition, aiding timing and targeting of therapeutic interventions, and determining the pathogenesis of the condition in patients. Conditions in which the level of protease inhibitors, such as PAI-1, is a useful marker are bleeding conditions characterized by an inability to produce PAI-1 or a lack of active PAI-1. Antibodies to the reactive site of a serpin protease inhibitor such as PAI-1 would be useful for distinguishing between active and latent forms of the protease inhibitor.

In another embodiment, antibodies to peptides identified using substrate subtraction libraries are also useful to identify novel active protease inhibitors. The antibodies may be used to identify molecules having exposed sequences similar to the sequences of peptides identified using substrate subtraction libraries. This embodiment also is useful for screening naturally occurring compounds for protease inhibitor activity in the process of drug discovery.

In a further embodiment, antibodies to the identified peptides can be used for affinity purification of the peptides identified by the present invention. The peptides to be purified can be in a mixture of peptides or can be peptides produced by recombinant techniques.

Suitable antibodies comprise immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab'

and F(ab')₂.

Brief Description of the Drawings

In the Drawings,

FIGURE 1 is a diagram depicting an outline of one protocol used
5 to create substrate subtraction libraries, where the gene III fusion protein, phage, monoclonal antibodies, and immobilized protein A are not drawn to scale;

FIGURE 2 is a diagram depicting an outline of another protocol used to create substrate subtraction libraries;

FIGURE 3 is a representation of the results of a functional analysis
10 of individual control or substrate phage stocks using a dot blot assay; and

FIGURE 4 is a representation of the results of a functional analysis of specific cleavage of a fusion protein by t-PA.

Detailed Description of Preferred Embodiments

The disclosed methods are useful general in the design of specific
15 inhibitors of various proteins and enzymes. The method can be applied to other proteases, and to other classes of enzymes, including kinases and phosphatases. Thus, the disclosures relating to u-PA and t-PA should be considered exemplary and not limiting.

Examples of other suitable enzyme systems include proteases,
20 including other serine proteases, as well as kinases and phosphatases.

The present invention relates to compositions including peptides and methods of identifying those peptides that are selectively reactive between a first enzyme and a second enzyme. A combinatorial library displaying different peptides is provided. This combinatorial library can be made, for example, by
25 random mutation of bacteriophages displaying peptide sequences. The phage express the peptide sequences externally and, after reaction with the enzymes, the desired phage can be enriched. Alternatively, the combinatorial library can include an array of peptide substrates whose amino acid sequences are known by their location on the substrate. The production of such library arrays on
30 substrates is well known in the art. See, for example, Meyers, Molecular

Biology and Biotechnology: A Comprehensive Desk Reference, VCM Publishers, New York 1995, pages 880-883. The use of a phage library is preferred because it is generally able to a greater range of different sequences, usually on the order of 10^8 different amino acid sequences.

5 The combinatorial library is contacted with the first enzyme to permit the first enzyme to modify some of the components of the combinatorial library. Those components which are modified by the first enzyme are then separated from the components of the library that are substantially unmodified by the first enzyme.

10 At that point, either one of two steps is then taken. The modified portion is contacted with the second enzyme or the unmodified portion is contacted with the second enzyme. It is then possible to identify at least some of the components of the combinatorial library that are modified by one enzyme but substantially unmodified by the other. A working example showing these
15 pathways is demonstrated in FIGURE 1. The example of phage displaying hexamer peptides with epitope tags on the end of the peptide is shown. The phage library is then allowed to contact the t-PA enzyme to digest the peptides. This results in the separation into two portions, those components which were modified by the t-PA are shown on the left and those not modified by the t-PA
20 are shown on the right. As shown, separation is accomplished by immobilizing with monoclonal antibodies.

 The phage that were modified by t-PA is then amplified to produce phage displaying the entire peptide and epitope tabs. As shown on the right, the phage were then digested with u-PA and the phage which were modified were
25 separated from unmodified phage by the use of monoclonal antibodies. This results in a first population of phage expressing peptides that react with both t-PA and u-PA. It also results in a second population that reacts with t-PA but not u-PA. It is the second population that is of interest in the present invention. This population can be resuspended and amplified.

30 Alternatively shown on the left side of FIGURE 1, the population

of phage that was unmodified by t-PA are resuspended and contacted with u-PA. After digestion, monoclonal antibodies are used as before. This results in two more populations, a third population which includes phage expressing peptides that react with u-PA but not t-PA, and a fourth population which includes phage
5 that did not react with either u-PA or t-PA. It is the third population which is also of interest in the present invention. This population can then be amplified.

As can be seen, both of these routes allow the identification of the some of the components of the combinatorial library that are modified by one enzyme but not modified by the other. As shown in FIGURE 1, these are the
10 third and fourth populations. The entire procedure or individual screening steps can be repeated one or more times to increase the selectivity.

At least some of the components that are modified by one enzyme but are not modified by the other enzyme are then identified. In the case of the phage library, phage in the second and third populations are identified in this
15 manner. The phage can then be grown in culture allowing the identification to also include determining the amino acid sequence of at least one of the displayed peptides. The resulting peptides have a selectivity preferably of at least 10 fold, and more preferably of at least 50 fold, for the desired enzyme compound to the undesired enzyme. The enzymes are preferably both proteases such as kinases
20 and phosphatases.

In the case of library arrays on substrates, portions of the library, such as the use of two identical arrays, are individually reacted with each of the enzymes. The location of peptide cleaving is determined, such as by use of a cysteine residue or an epitope tag and labeled antibodies on each array and the
25 results compared to determine which peptides react with one enzyme but not the other.

The amino acid sequence or sequences that are determined can then be used to make peptides having these sequences. These peptides can be used to prepare antibodies as is known in the art and used to purify recombinant peptides
30 or identify naturally occurring protease inhibitors which are immunoreactive with

the antibodies so produced. The antibodies are also used for diagnostic assays which can distinguish between active and latent forms of the protease inhibitors.

The amino acid sequences determined can be used to engineer protease inhibitors. For example, the amino acid sequence determined to be
5 highly selective toward to the second enzyme can be used in the design of an inhibitor for the second enzyme which has a low reactivity with the first enzyme. This allows the treatment of medical conditions where targeting of inhibition of the second enzyme is useful, while inhibiting the first enzyme is not desired.

Such inhibitors would have a structure corresponding to naturally
10 occurring enzyme inhibitors. The amino acid sequence of such inhibitors would be modified to include the amino acid sequence taught by the method of this invention. Alternatively, substrates including amino acid sequences as taught by the present invention are modified to create inhibitors.

The amino acid sequence, together with the other coding for the
15 inhibitor is then coded on a plasmid or other DNA vector for introduction into a prokaryotic or eukaryotic cell as is well known in the art. Such cells will produce the desired enzyme inhibitor which can be purified using the antibodies discussed above.

A substrate subtraction combinatorial library can also be produced.
20 The combinatorial library is contacted with the first enzyme to modify some of the components of the combinatorial library. The phage can then be separated by solid phase or precipitation as known in the art with either population serving as a substrate subtraction library. The example of the first enzyme will be used.

Such a substrate subtraction library substantially lacks peptides that
25 are effective substrates for the first enzyme, meaning that the peptides have a reactivity of less than about 10 percent of the best naturally occurring molecule that the first enzyme reacts with. For example, in the case of u-PA as shown in Table 5 below, the native or wild type PAI-1 has a rate constant of $1.9 \times 10^7 \text{ M}^{-1} \text{ s}^{-1}$ while the selected PPAI-1/P3R has a rate constant of 1.0×10^5 meaning that
30 the reactivity is less than 1 percent. Table 8 also makes similar comparisons with

the wild type. The peptides in the combinatorial library preferably have a k_{cat}/K_m ratio of less than about $500 \text{ M}^{-1}\text{s}^{-1}$ and preferably a k_{cat}/K_m ratio of less than about $100 \text{ M}^{-1}\text{s}^{-1}$.

5 While the removal of the peptides that are effective substrates for the first enzyme is preferred for preparing a substrate subtraction library, it is not necessary for practicing the invention. Depending on the enzyme involved, the method for the present invention can be practiced with peptides having a reactivity even greater than 10% when compared to the naturally occurring molecule.

10 The present invention also provides for therapeutic treatment of a patient. This treatment can take two general forms. The determined peptide itself can be administered to the patient to in effect overload the patient's enzymes thereby creating an inhibitory effect. In such cases, the preferred administration rates of the peptides, such as t-PA and u-PA, are from about 0.1
15 micrograms/kg to about 50 micrograms/kg.

Alternatively, enzyme inhibitors made according to the present invention can also be administered to the patient. These inhibitors directly inhibit the activity of the enzymes. In the case of u-PA and t-PA, the preferred administration rates are from about 0.003 micrograms/kg to about 20
20 micrograms/kg.

Some of the diseases that can be effectively treated are serpin deficiencies such as pulmonary emphysema, associated with deficiencies of α_1 -proteinase inhibitor, antithrombin deficiency, hereditary angioedema associated with deficiencies of C1- inhibitor, bleeding disorders associated with deficiencies
25 in α -antiplasmin or PAI-1 (Gettins et al. 1996). Serpins have also been implicated in several forms of cancer, including squamous cell carcinoma (Gettins, et al. 1996). In each case, a physiologically effective amount of the peptide or the enzyme inhibitor is administered. Examples of specific peptides are discussed below.

30 Referring to FIGURE 2, the specific example of phage having

hexamer peptides and epitope tags are disclosed. This example pre-processes the library to enhance selectivity. The phage library is then contacted with the t-PA enzyme and digested. Monoclonal antibodies to the epitope tags are then added to separate cleaved and uncleaved expressed peptides. The phage having cleaved
5 peptides are then selected and amplified. The amplified phage are then again digested with u-PA. Monoclonal antibody to the epitope tags is again used to immobilize the phage having peptides that were not modified by the u-PA. The undigested phage are then recovered and resuspended. They are again digested with t-PA and the unreacted phage are again separated using monoclonal
10 antibodies. The phage which are again reacted with t-PA are then identified in the supernatant.

EXAMPLE 1:

Preparation and Use of Substrate Subtraction Libraries

Reagents.

15 Competent MC1061 (F-) E. coli and nitrocellulose were purchased from Bio-Rad Laboratories. Pansorbin (Protein A-bearing S. aureus) cells were obtained from Calbiochem (San Diego, CA). K91 (F+) and MC1061 (F-) strains of E. coli were provided by Steve Cwirla (Affymax). MAb 3-E7 was purchased from Gramsch Laboratories (Schwabhausen, FRO). u-PA was obtained from Jack
20 Henkin (Abbott Laboratories).

A polyvalent fd phage library that displayed random hexapeptide sequences and contained 2×10^8 independent recombinants was prepared (Ding, C., et al., 1995; Smith, M.M., et al, 1995). Peptides were synthesized and purified as described (Madison, E. L., et al. (1995) J. Biol. Chem.
25 270,7558-7562.). Each member of this library displayed an N-terminal extension from phage coat protein III (pIII) containing a randomized region of six amino acids fused to pIII, followed by a six residue linker sequence (SSGGSG) and the epitopes for mAb 179 and mAb 3-E7. Because neither t-PA or u-PA digests the pIII sequence, the antibody epitopes, or the flexible linker sequence, the loss of
30 antibody epitopes from the phage surface upon incubation with either enzyme

requires cleavage of the randomized peptide insert. Incubation of the library with t-PA, followed by removal of phage retaining the antibody epitopes, therefore, accomplishes the enrichment of phage clones whose random hexamer sequence can be cleaved by t-PA.

5 The detailed construction of the phage vector fAFFI-tether C (fTC) and the random hexapeptide library fAFF-TC-LIB has been previously described (Smith, M.M., et al, 1995). Control substrate phage frC-PL, which contained the physiological target sequence for u-PA and t-PA, was constructed by hybridizing the single stranded oligonucleotides

10 5'-TCGAGCGGTGGATCCGGTACTGGTCGTCGTCATGCTCTGGTAC-3'
and 5'-CGCCACCTAGGCCAGGACCAGCACAACAACCACGAGAC-3' and
then ligating the annealed, double stranded products into the Xho I/Kpn I-cut vector frC. All constructs were first transformed into MCI061 by electroporation and then transferred into K91.

15 Measurement of Enzyme Concentrations.

Concentrations of functional t-PA and u-PA were measured by active site titration with 4-methylumbelliferyl p-guanidinobenzoate (Jameson, G., et al., (1973) Biochem. J. 131, 107-117) using a Perkin-Elmer LS 50B Luminescence Fluorometer as previously described (Madison, E.L., et al., (1995) J. Biol. Chem. 270: 7558-7562). In addition, the enzymes were titrated with a
20 standard PAI-1 preparation that had been previously titrated against a trypsin primary standard. Total enzyme concentrations were measured by ELISA.

The procedure used in producing substrate subtraction libraries is outlined in FIGURE 2. The initial phage library was subjected to three rounds of
25 high stringency selection with t-PA to assure the preparation of an intermediate library that is highly enriched for phage that are very good substrates of t-PA. This intermediate library was then digested at low stringency with u-PA to remove phage that are moderate or good substrates for u-PA. Substrate subtraction was accomplished after the protease digestion of phage by adding Mab
30 3E-7 and immobilized protein A (Pansorbin cells, Calbiochem, San Diego, CA)

to the reaction mixture and precipitating the ternary complexes which contain the undigested phage.

In contrast to earlier three rounds of selections, phage remaining in solution were then discarded, and the precipitate containing the ternary complexes is resuspended. Phage that were preferentially cleaved by t-PA were then identified by their release from the ternary complexes by digestion at high stringency with t-PA.

Preparation and Sequencing of DNA from Phage Clones.

DNA samples were prepared from identified phage clones as previously described (Ding, C., et al., (1995)). Briefly, phage are precipitated from a 1 ml overnight culture by adding 200 μ l of 20% polyethylene glycol in 2.5 M NaCl. The mixture was incubated on ice for 30 min., and the phage pellet was collected by microcentrifugation for 5 min. The phage were resuspended in 40 μ l lysis buffer (10 mM Tris-HCL, pH 7.6, 0.1 mM EDTA, 0.5% Triton X-100) and heated at 80 C for 15 min. Single stranded DNA was purified by phenol extraction and ethanol precipitation and sequenced according to the method of Sanger.

The kinetic analysis of particular clones is summarized in Table 1. Tables 2 and 3 summarize the sequences of other additional clones. Table 2 shows the sequences of 37 t-PA - selective phage clones isolated and functionally verified containing 32 distinct substrate sequences. For comparison, the sequences of six u-PA selective clones are listed in Table 2.

To verify that the substrate subtraction library had yielded substrates that were preferentially cleaved by t-PA, digestion of individual phage stocks by t-PA and u-PA was analyzed by a dot blot assay that was performed as previously described (Ding, L., et al., 1995; Smith, M.M., et al., 1995) (FIGURE 3). Loss of positive staining indicates loss of antibody epitopes from the phage due to proteolytic cleavage of the random hexamer region. Control phage PL contains the P3 - P3' region of the actual target sequence present in plasminogen (PGRVVG, residues 4-9 of SEQ ID NO:1) and was not digested by

either enzyme under the conditions used in this test. Substrate phage 51 contained the hexamer RIARRA (SEQ ID NO:148) and was a substrate of both t-PA and u-PA. Phage 7 contained the hexamer FRGRAA (SEQ ID NO:25) and was a t-PA selective substrate. Phage 33 contained the hexamer RSANAI (SEQ ID NO:51) and was a u-PA selective substrate.

Kinetics of Cleavage of Synthetic Peptides by t-PA and u-PA.

Individual phage stocks were prepared and digested with no enzyme, t-PA, u-PA, or u-PA in the presence of 1 mM amiloride, a specific inhibitor of u-PA. Kinetic data were obtained by incubating various concentrations of peptide with a constant enzyme concentration to achieve between 5 and 20% cleavage of the peptide in each reaction. For assays with u-PA, enzyme concentration was either 815 or 635 nM. For assays with t-PA enzyme concentration was 700 nM. Peptide concentrations were chosen where possible to surround K_m and in all cases were between 0.5 and 32 mM. The buffer used in these assays has been described (Madison, E. L., et al., 1995). Reactions were stopped by addition of trifluoroacetic acid to 0.33% or by freezing on dry ice. Cleavage of the 13 and 14 residue peptides was monitored by reverse phase HPLC as described (Madison, E. L., et al., 1995). The 4-6 residue peptides were acylated at their amino termini and amidated at their carboxyl termini. Cleavage of the 4-6 residue peptides was monitored by hydrophilic interaction HPLC chromatography (HILIC) (Alpert, A. J. (1990) J. Chromatog. 499, 177-196.) using a polyhydroxyaspartamine column from PolyLC (Columbia, MD). Buffer A was 50 mM triethylamine phosphate in 10% acetonitrile and buffer B was 10 mM triethylamine phosphate in 80% acetonitrile. Peptides were eluted by a gradient which was varied from 100% Buffer B to 100% Buffer A during a 13 minute interval. The percent of cleaved peptide was calculated by dividing the area under the product peaks by the total area under substrate and product peaks. For all peptides containing multiple basic residues, mass spectral analysis of products confirmed that cleavage occurred at a single site and identified the scissile bond. Data were interpreted by Eadie-Hofstee

analysis. Errors were determined as described (Taylor, J. R., 1982) An introduction to error analysis. The study of uncertainties in physical measurements. University Science Books, Mill Valley, California.) and were <25%.

5 The results of kinetic analysis are summarized in Table 1, below, which compares the values determined for cleavage of the native target, plasminogen (I), t-PA selective peptides (II-X) and u-PA selective peptides (XI-XVIII).

10 Three peptide substrates (II - IV) containing hexamer sequences present in individual members of the substrate subtraction library were synthesized and characterized to provide a quantitative analysis of the properties of putative t-PA selective substrates. These peptides were cleaved between 13 and 47-fold more efficiently by t-PA than by u-PA (Table 1).

15 Comparison of the hexamer sequences obtained from the substrate subtraction library and the consensus sequences derived for substrates of u-PA and t-PA confirms the expected intimate similarity between optimal sub-site occupancy for these two closely related enzymes. In addition, these data strongly suggest that the P3 residue of a substrate is the primary determinant of the ability to distinguish between t-PA and u-PA. t-PA prefers arginine or large
20 hydrophobic residues at this position while u-PA favors small hydrophilic residues, particularly serine.

 In contrast to results obtained using t-PA, standard phage display was sufficient to yield highly selective u-PA substrates. One hundred substrate phage, containing 89 distinct random hexamer sequences, were selected using
25 u-PA (Table 4). Dot blot analysis of the individual phage stocks under increasingly stringent conditions indicated that eleven clones, containing eight distinct hexamer sequences, were particularly labile u-PA substrates (Table 3). Peptides containing four of these eight hexamer sequences (XI - XIV) were synthesized and characterized. All four peptides were substantially improved
30 substrates for u-PA, by factors of 840 - 5300, compared to a control peptide (I)

that contained the actual target sequence present in plasminogen (Table 3). The four peptides were also cleaved 16 - 89 times more efficiently by u-PA than by t-PA.

To confirm the key role of P3 in defining specificity differences
5 between t-PA and u-PA, variants of a u-PA selective peptide that contained either tyrosine or arginine at this position were synthesized and characterized. In striking contrast to parent peptide XI, the two variants (peptides VIII and IX) were cleaved 5.2-5.7 times more efficiently by t-PA than by u-PA, a 320-fold reversal in substrate preference (Table 1). Further replacement of the glycine
10 found at P4 of the u-PA selective substrate with glutamine (peptide X) increased t-PA selectivity to 19-fold over u-PA. Point mutations at both P4 and P3, therefore, altered the relative specificity of t-PA versus u-PA by a factor of 1200.

The kinetic analysis described above was performed using substrate peptides that were 14 amino acids in length. To confirm that the specificity we
15 observed was inherent in the selected hexapeptide sequences, and therefore would be expected to be readily converted into viable, small molecule peptidomimetics, we examined the kinetics of cleavage of short peptides containing only sequences found within selected hexapeptide sequences. For both t-PA and u-PA selective substrates, specificity was maintained by related pentapeptides. The peptide
20 FRGRK was cleaved approximately 74 times more efficiently by t-PA than by u-PA while the peptide GSGKS was hydrolyzed approximately 120 times more efficiently by u-PA than by t-PA (Table 1). The relative specificity of these two pentapeptides for cleavage by t-PA versus u-PA, therefore, differs by a factor of approximately 9000, indicating that appropriate occupancy of the P4 - P1' sub-
25 sites alone can mediate the ability of a substrate to distinguish the closely related enzymes t-PA and u-PA.

To define further the extent of substrate discrimination that could be achieved in other structural contexts, the t-PA selective hexapeptide QRGRSA was introduced into a fusion protein consisting of a photoreceptor protein linked
30 to maltose binding protein. t-PA readily cleaved the fusion protein (FIGURE 4)

whereas u-PA did not, demonstrating the maintenance of specificity for cleavage of this selected, primary sequence in the structural context of a protein substrate.

The fusion consists of maltose binding protein fused to the amino terminus of the HY4 gene product of Arabidopsis thaliana with a linking region
5 in between coding for the amino acid sequence QRGRSA, which is cleaved by
t-PA between R and S. The concentration of fusion protein in each lane is 1.4
mM and the concentration of u-PA or u-PA is 150 nM. The reaction buffer
contains 50 mM Tris pH 7.5, 0.1 M NaCl, 1 mM EDTA, and 0.01 % Tween 20.
Reactions were set up in a total volume of 20 mL and allowed to incubate 16
10 hours at 25 C and then stopped by the addition of 5 mL of 5X loading buffer and
separated by electrophoresis on 12% polyacrylamide. The gel was stained with
Coomassie Brilliant Blue 30 minutes and de-stained overnight.

Table 1. Comparison of k_{cat} and K_m and k_{cat}/K_m for hydrolysis of peptides selected for preferential cleavage by t-PA or u-PA

5	Substrate '(Pn..P3,P2,P1,↓P1',P2',P3'..Pn)	SEQ ID NO:	t-PA			u-PA			t-PA:u-PA Selectivity
			k_{cat} s ⁻¹	K_m (μ M)	k_{cat}/K_m (M ⁻¹ s ⁻¹)	k_{cat} s ⁻¹	K_m (μ M)	k_{cat}/K_m (M ⁻¹ s ⁻¹)	
10	(I) KKSPGR↓VGGGVAH	1	0.0043	15000	0.29	0.003	3400	0.88	0.33
	(II) LGGGQRGR↓KALE	2	0.99	2300	430	0.02	2180	9.2	47
	(III) LGGGERAR↓GALE	3	0.073	1410	52	0.004	970	4.0	13
	(IV) LGGSGHYGR↓SGLE	4	1.29	4010	322	0.059	3800	15	21
15	(V) YGR↓S	5	23.7	6000	3950	2.6	11400	230	17
	(VI) RGR↓K	6	15.3	16600	992	0.76	46500	16	57
	(VII) FRGR↓K	7	12.2	9800	1240	0.14	8600	16	78
	(VIII) LGGYGR↓SANAILE	8	3.29	1850	1800	0.7	2200	318	5.7
20	(IX) LGGRGR↓SANAILE	9	0.85	2400	350	0.08	1200	67	5.2
	(X) LGQRGR↓SANAILE	10	2.55	3000	850	0.068	1500	45	19
	(XI) LGGSGR↓SANAILE	11	0.305	4080	75	2.83	603	4700	0.016
	(XII) LGGSGR↓NAQVRLE	12	0.255	7000	36	3.69	1160	3200	0.011
25	(XIII) LGGSGR↓SATRDLE	13	0.068	1500	45	0.54	733	740	0.06
	(XIV) LGGSGR↓KASLSLE	14	0.168	5100	33	1.14	1130	1010	0.032
	(XV) SGR↓S	15	5.0	15000	330	2.3	2100	1100	0.30
	(XVI) SGR↓SA	16	2.4	40000	60	3.7	3100	1200	0.05
	(XVII) SGK↓S	17	0.19	28000	6.8	1.22	7900	154	0.04
	(XVIII) GSGK↓S	18	0.07	44000	1.6	0.82	4250	193	0.008

¹Positional nomenclature of subsite residues. Arrows denote the position of peptide bond hydrolysis. The peptide bond is cleaved between P1 and P1'. The error in these determinations was 4-22%.

Table 2: Primary sequences of hexamers of t-PA selective substrate clones

	SEQ ID	Clone	P5	P4	P3	P2	P1	P1'	P2'	P3'	P4'	P5'
5	19	1			A	L	R	R	G	D		
	20	2	D	Y	R	G	R	M	(L)			
	21	3		E	R	A	R	G	A			
	22	4		E	R	L	R	K	A			
10	23	5			F	G	R	H	A	A		
	24	6		F	L	P	R	T	A			
	25	7		F	R	G	R	A	A			
	26	8		H	R	M	R	M	G			
	27	9		H	Y	G	R	S	G			
15	28	10			I	M	R	R	G	K		
	29	11	I	T	Y	G	R	R	(L)			
	30	12		K	F	T	R	S	G			
	31	13		L	I	P	R	R	A			
	32	14	M	T	R	K	R	M	(L)			
20	33	15		N	F	A	R	M	G			
	34	16		N	H	L	R	K	A			
	35	17		N	V	G	R	M	G			
	36	18		N	V	S	R	R	G			
	37	19		P	I	S	R	R	A			
25	38	20		P	V	G	R	M	G			
	39	21		Q	R	L	R	K	A			
	40	22		R	L	G	R	S	V			
	41	23		S	F	G	R	R	H			
	42	24	S	L	R	G	R	S	(L)			
30	43	25		T	V	L	R	R	A			
	44	26			V	A	R	R	V	K		
	45	27		V	I	A	R	S	N			
	46	28		V	N	T	K	S	G			
	47	29		V	R	A	R	G	A			
35	48	30	V	R	R	G	R	S	(L)			
	49	31		V	R	R	R	G	A			
	50	32		T	R	V	R	A	K			

40

TABLE 3: Primary sequences of hexamers of most labile u-PA substrate clones

	SEQ ID	Clone	P5	P4	P3	P2	P1	P1'	P2'	P3'	P4'	P5'
	51	33			(S	G)	R	S	A	N	A	I
45	52	34			(S	G)	R	N	A	Q	V	R
	53	35			(S	G)	R	S	A	T	R	D
	54	36			(S	G)	R	S	A	K	V	D
	55	37			(S	G)	R	K	A	S	L	S
	56	38			(S	G)	R	R	A	V	S	N
50	57	39			(S	G)	R	S	A	V	V	K
	58	40			(S	G)	R	S	S	S	S	H

TABLE 4: u-PA-Phage Selection Summary

SEQ ID	SELECTIVITY	P5	P4	P3	P2	P1	P1'	P2'	P3'	P4'	P5'
5	59 (U,T)		A	I	K	R	S	A			
	60 (U)				G	R	R	G	N	R	
	61 (U)				G	R	S	V	N	N	
	62 (U)			H	T	R	R	M	K		
	63 (U,T)	I	S	T	A	R	M				
10	64 (U)					K	A	A	D	V	T
	65 (U)					K	K	R	T	N	D
	66 (U)	K	M	S	A	R	I				
	67 (U)				K	R	R	D	V	A	
	68 (U)				K	R	V	S	K	N	
15	69 (U)					K	S	A	D	A	A
	70 (U)					R	A	A	A	M	V
	71 (U)					R	A	A	N	I	R
	72 (U)					R	A	H	R	D	N
	73 (U)					R	A	R	D	D	R
20	74 (U)					R	A	R	H	M	V
	75 (U)					R	A	R	S	P	R
	76 (U)					R	A	V	G	H	Q
	77 (U)					R	A	V	V	D	S
	78 (U)					R	G	G	K	G	P
25	79 (U,T)					R	G	R	S	A	V
	80 (U)					R	G	V	D	M	N
	81 (U)					R	G	V	K	M	H
	82 (U)					R	H	R	S	D	I
	83 (U)					R	K	G	Q	G	G
30	84 (U)					R	K	L	H	M	N
	85 (U)					R	K	M	D	M	G
	86 (U)					R	K	M	D	R	S
	87 (U)					R	K	M	R	M	G
	88 (U)					R	K	N	Q	R	V
35	89 (U)					R	K	Q	R	D	S
	90 (U)					R	K	R	V	G	A
	91 (U)					R	K	S	K	V	V
	92 (U)					R	K	S	T	S	S
	93 (U)					R	K	V	G	S	L
40	94 (U)					R	K	V	P	G	S
	95 (U)					R	K	W	I	S	G
	96 (U)					R	L	A	T	K	A
	97 (U)					R	M	R	K	N	D
	98 (U)					R	N	A	Q	V	R
45	99 (U,T)					R	N	A	V	E	P
	100 (U)					R	N	D	R	L	N
	101 (U)					R	N	G	K	S	R
	102 (U)					R	N	M	P	L	L
	103 (U)					R	N	T	G	S	H
50	104 (U)					R	R	M	T	M	G
	105 (U)					R	R	R	L	N	M
	106 (U)					R	R	T	L	D	F
	107 (U,T)					R	R	S	A	K	V
	108 (U)					R	R	S	A	N	A
55	109 (U)					R	R	S	A	T	D

TABLE 4 continued: u-PA-Phage Selection Summary

SEQ	ID	SELECTIVITY	P5	P4	P3	P2	P1	P1'	P2'	P3'	P4'	P5'
5	110	(U)					R	S	A	V	V	K
	111	(U)					R	S	D	Q	F	L
	112	(U)					R	S	D	N	P	N
	113	(U)					R	S	E	R	S	L
	114	(U)					R	S	G	D	P	G
10	115	(U)					R	S	G	N	T	T
	116	(U)					R	S	G	N	M	G
	117	(U)					R	S	N	G	V	G
	118	(U)					R	S	P	D	G	M
	119	(U)					R	S	R	R	L	P
15	120	(U)					R	S	R	V	T	S
	121	(U)					R	S	S	H	S	S
	122	(U)					R	S	S	Q	A	A
	123	(U)					R	S	S	S	S	H
	124	(U)					R	S	S	S	T	V
20	125	(U)					R	S	T	D	L	G
	126	(U)					R	S	T	N	V	E
	127	(U)					R	S	T	R	H	K
	128	(U)					R	S	Y	T	N	S
	129	(U)					R	T	S	P	S	T
25	130	(U)					R	T	S	V	N	L
	131	(U)			S	G	R	A	R	Q		
	132	(U)			S	K	R	A	S	I		
	133	(U)			S	K	S	G	R	S		
	134	(U)	S	Q	T	C	V	R				
30	135	(U)			S	S	R	N	A	D		
	136	(U)			T	A	R	L	R	G		
	137	(U)			T	A	R	S	D	N		
	138	(U)			T	E	R	R	V	R		
	139	(U)			T	Q	R	R	T	G		
35	140	(U)			T	T	R	R	D	R	I	
	141	(U)			T	S	R	R	M	G	T	
	142	(U)			T	S	R	R	Q	A	Q	
	143	(U)			T	T	R	R	N	K		
	144	(U)			T	T	S	R	R	S		
40	145	(U,T)			V	A	R	R	M	Y	K	
	146	(U,T)			V	S	R	R	N	M		
	147	(U,T)			W	S	G	R	S	G		

EXAMPLE 2:

Preparation of Specific Inhibitors of t-PA

Specific inhibitors of t-PA were designed using the sequences derived in Example 1 by making variants of the PAI-1, natural inhibitor of t-PA.

5 Site-directed Mutagenesis and Construction of an Expression Vector Encoding a Recombinant Variant of PAI-1.

The expression vector pPAIST7HS was derived from the plasmid pBR322 and contained a full length cDNA encoding human PAI-1 that was transcribed from a T7 gene 10 promoter (Tucker, H. M., et al., (1995) Nature
10 Struct. Biol. 2: 442-445). The 300 bp Sal I/Bam HI fragment of human PAI-1 was subcloned from pPAIST7HS into bacteriophage M13mp18. Single stranded DNA produced by the recombinant M13mp18 constructs was used as a template for site specific mutagenesis according to the method of Zoller and Smith (Zoller, M. I., and Smith, M. (1984) DNA 3, 479-488) as modified by Kunkel (Kunkel,
15 T. A. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 488-492).

Expression of wild type and the mutated variant of PAI-1 was accomplished in the E. coli strain BL21[DE3]pLys^s (Novagen, Madison, WI) which synthesizes T7 RNA polymerase in the presence of isopropylthio-B-D-galactoside (IPTG). Bacterial cultures were grown at 37 degrees Celsius with
20 vigorous shaking to an A₅₉₅ of 0.9-1.1, and IPTG was added to a final concentration of 1 mM to induce the synthesis of T7 RNA polymerase and the production of PAI-1 proteins. Cultures were grown for an addition 1-2 hrs at 37 degrees Celsius and then shifted to 30 degrees Celsius for 2-6 hours.

Cells were pelleted by centrifugation at 8000 X g for 20 min at 4
25 degrees Celsius and resuspended in 40 ml of cold start buffer (20 mM Sodium Acetate, 200 mM NaCl and 0.01% Tween 20, pH 5.6). The cell suspension was disrupted in a French pressure cell (Aminco), and cellular debris was removed by ultracentrifugation for 25 min at 32000 X g.

Purification of soluble, active PAI-1 was performed as previously
30 described (Sancho, E., et al., (1994) Eur. J. Biochem. 224: 125-134). PAI-1

containing supernatants were injected onto a XK-26 column (Pharmacia Biotech) packed with CM-50 Sephadex (Pharmacia). The column was washed with 5 column volumes of start buffer (20 mM Sodium Acetate, 200 mM NaCl and 0.01 % Tween 20, pH 5.6), and PAI-1 proteins were eluted using a 0.2 M - 1.8 M linear gradient of NaCl in the same buffer. Peak fractions were collected, pooled, and concentrated using a Centriplus 30 concentrator (Amicon). Purified preparations were analyzed by activity measurements using standard, direct assays of t-PA, SDS-PAGE, and measurement of optical density at 280 nm.

Measurement of Active PAI-1 in Purified Preparations.

A primary standard of trypsin was prepared by active site titration using p-nitrophenyl-guanidinobenzoate HCl as described previously (Chase, T., and Shaw, E. (1967) *Biochem. Biophys. Res. Commun.* 29: 508-514). Concentrations of active molecules in purified preparations of wild type or mutated PAI-1's were determined by titration of standardized trypsin as described by Olson et al. (Olson, S. T., et al., (1995) *J. Biol. Chem.* 270: 30007-30017) and by titration of standardized t-PA preparations.

Kinetic Analysis of the Inhibition of t-PA and u-PA by Recombinant PAI-1 and PAI-1/UKI.

Second order rate constants (k_i) for inhibition of t-PA or u-PA were determined using pseudo-first order ($k_i < 2 \times 10^6$) or second order ($k_i > 2 \times 10^6$) conditions. For each reaction, the concentrations of enzyme and inhibitor were chosen to yield several data points for which the residual enzymatic activity varied between 20%-80% of the initial activity. Reaction conditions and data analysis for pseudo-first order reactions were as previously described.

For second order reactions, equimolar concentrations of u-PA and PAI-1 were mixed directly in microtiter plate wells and preincubated at room temperature for periods of time varying from 0 to 30 minutes. Following preincubation the mixtures were quenched with an excess of neutralizing anti-PAI-1 antibody (generously provided by Dr. David Loskutoff), and residual

enzymatic activity was measured using a standard, indirect chromogenic assay. These indirect, chromogenic assays were compared to control reactions containing no PAI-1 or to which PAI-1 was added after preincubation, addition of anti-PAI-1 antibody, plasminogen, and Spec PL to the reaction mixture. Data were analyzed by plotting the reciprocal of the residual enzyme concentration versus the time of preincubation.

To test the prediction, based on an analysis of the cleavage of peptide substrates, that the P3 residues can mediate the ability of an inhibitor to discriminate between t-PA and u-PA, site-specific mutagenesis was performed on PAI-1, the primary physiological inhibitor of both t-PA and u-PA.

Three variants of PAI-1 were produced and characterized. The first was a variant in which the P3 serine (Ser 344) was converted to an arginine residue. The second was a variant in which the P4 valine (Val 343) was replaced by a glutamine residue. The third variant was a double mutant in which both of the substitutions were made.

Kinetic analysis of the inhibition of both t-PA and u-PA by these variants of PAI-1 was consistent with the tests based on the peptide substrates. The second-order rate constants for inhibition of t-PA and u-PA by wild type PAI-1 were $1.6 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ and $1.9 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$, respectively. Thus, wild-type PAI-1 shows about 11.9-fold specificity toward u-PA.

In contrast, the second-order rate constants for inhibition of t-PA and u-PA by the P3 arginine mutant PAI-1 were, respectively, $1.4 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ and $1.0 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$, an approximately 170-fold reversal in specificity toward t-PA. This large change in specificity was achieved without sacrificing activity toward the target enzyme. The P3 arginine mutation reduced activity of PAI-1 toward u-PA by a factor of about 190 without significantly affecting reactivity toward t-PA.

An individual mutation of the P4 valine to a glutamine had no effect on the rate of inhibition of either t-PA or u-PA. As suggested by the predominance in the subtraction library of substrates containing both large P3 and

- 28 -

large P4 residues, the P4 glutamine mutation did increase the t-PA selectivity of the P3 arginine variant of PAI-1. The second order rate constants for the inhibition of t-PA and u-PA by this double mutant PAI-1 were, respectively, $1.4 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ and $2.9 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$. While maintaining full activity toward t-PA, the double mutant showed an approximately 600-fold enhanced t-PA/u-PA selectivity compared to wild-type PAI-1 and about a 3.5-fold greater t-PA selectivity than the P3 arginine variant of PAI-1. The absolute t-PA/u-PA selectivity of wild-type PAI-1, the P3 arginine single mutant and the P3 Arg, P4 Gln double mutant was 0.08, 14, and 48, respectively.

10

Table 5:
Second order rate constants for inhibition of t-PA or u-PA
by wild type PAI-1 and variants of PAI-1

Inhibitor	SEQ ID NO:	Primary Sequence of reactive center loop (P4-P2')	Rate constant toward t-PA $\text{M}^{-1}\text{s}^{-1}$	Rate constant toward u-PA $\text{M}^{-1}\text{s}^{-1}$	t-PA/u-PA Selectivity
Wild type PAI-1	149	VSAR↓MA	1.6×10^6	1.9×10^7	0.08
PAI-1/P3R	150	VRAR↓MA	1.4×10^6	1.0×10^5	14
PAI-1/P4Q	151	QSAR↓MA	1.6×10^6	1.9×10^7	0.08
PAI-1/P4Q,P3R	152	QRAR↓MA	1.4×10^6	2.9×10^4	48

15

EXAMPLE 3:

20

Preparation of Specific Inhibitors of Urokinase

Substrate phage display alone, without subtractive substrate screening, was to identify peptides that are cleaved 840-5300 times more efficiently by u-PA than peptides containing the wild type physiological target sequence of the enzyme. In addition, the peptide substrates selected were cleaved as much as 120 times more efficiently by u-PA than by t-PA.

25

In general, with the exception of the screening protocol, procedures followed were those used in Example 1. Digestion of the phage was performed using enzyme concentrations varying from 2 - 10 $\mu\text{g/ml}$ and incubation times varying from 0.5 - 10 hours. Phage precipitation and dot blot analysis were

performed as described in Example 1. Individual phage stocks were prepared and digested with no enzyme, t-PA, u-PA, or u-PA in the presence of 1 mM amiloride, a specific inhibitor of u-PA' for periods of time varying from 15 minutes to 10 hours. Individual reaction mixtures were spotted onto a
5 nitrocellulose filter using a dot blotter apparatus (BioRad). The filter was probed with MAb 3E-7 and developed using the Amersham Western ECL kit. Loss of positive staining indicates loss of antibody epitopes from the phage due to proteolytic cleavage of the randomized hexamer region.

Kinetic data were obtained by incubating various concentrations of
10 peptide with a constant enzyme concentration to achieve between 5 and 20% cleavage of the peptide in each reaction as described in Example 1.

A polyvalent fd phage library that displayed random hexapeptide sequences and contained 2×10^8 independent recombinants was prepared. Each member of this library displayed an N-terminal extension from phage coat protein
15 III (pIII) that contained a randomized region of six amino acids, a six residue linker sequence (SSGGSG), and the epitopes for mAb 179 and mAb 3-E7. Because u-PA did not digest the pIII sequence, the antibody epitopes, or the flexible linker sequence, the loss of antibody epitopes from the phage surface upon incubation with u-PA required cleavage of the randomized peptide insert.
20 Incubation of the library with u-PA, followed by removal of phage retaining the antibody epitopes, therefore, accomplished a large enrichment of phage clones whose random hexamer sequence could be cleaved by u-PA.

Following five rounds of selection to enrich and amplify phage which display sequences that are readily cleaved by u-PA, 100 phage clones were
25 identified as u-PA substrates. DNA sequencing of these clones revealed the presence of 91 distinct hexamer sequences among the selected phage (Table 6, below). As expected from the trypsin-like primary specificity of u-PA, each hexamer contained at least one basic residue, and 89 of the 91 hexamer sequences contained at least one arginine residue. 35 of the 91 substrate phage contained a
30 single basic residue, and in 33 of these 35 cases the single basic residue was an

arginine. An additional 22 phage contained two basic residues but only a single arginine. Alignment and analysis of these hexamer sequences suggested that the consensus sequence for optimal subsite occupancy for substrates of u-PA, from P3 - P2', was SGR(S>R,K,A)X, where "X" represents a variety of amino acid residues but is most often alanine, glycine, serine, valine, or arginine.

Analysis of these data was complicated by the fact that approximately 72% of the selected substrate phage contained an arginine in the first position of the randomized hexamer and therefore utilized the amino terminal flanking residues, Ser-Gly, to occupy the P3 and P2 subsites. While these results left no doubt that the P3-PT SGR sequence created by the fusion was a very favorable recognition site for u-PA, this use of flanking residues necessitated a particularly careful examination of the P3 and P2 preferences of u-PA.

Two changes were made in the experimental protocol to examine the P3 and P2 preferences of u-PA. First, an unusually large collection of substrate phage (91) were isolated to assure that a reasonable number of these (23) would not utilize the flanking Ser-Gly to fill the P3 and P2 subsites. This allowed a meaningful comparison of the consensus sequence derived from the entire library with that derived from the non-fusion phage and the demonstration of good agreement between the two consensus sequences. Second, dot blot analysis was performed as described in Example 1 on all 100 substrate phage using a wide variety of stringencies of digestion by u-PA. Although this semi-quantitative assay cannot provide kinetic constants, it can provide an accurate rank ordering of the lability of the substrate phage clones.

Under the most stringent conditions examined, 11 of the 100 substrate phage, containing 8 distinct randomized hexamer sequences, proved to be particularly labile u-PA substrates. The sequences were the same as those listed in Table 3, above. All 8 of the most labile substrate phage contained the P3-P1 SGR motif, demonstrating that this sequence is, in fact, a more labile u-PA site than related, selected sequences present in the library such as SSR, TAR, TSR, TTR, etc. This dot blot analysis also yielded additional information

regarding the preferences of u-PA for the unprimed subsites. While analysis of the entire substrate phage library failed to reveal a clear consensus at P1' and P2', the most labile substrate phage displayed an obvious preference at both of these positions. Five of the eight most labile phage contained a serine residue at P1',
5 and seven of these eight phage contained an alanine residue at P2'. These observations strongly suggest that the primary sequence SGRSA, from P3-P2', represents optimal subsite occupancy for substrates of u-PA.

Table 6. Amino acid sequences of the hexapeptide in 89 isolated substrate phage clones.

	Clone Number	Amino acid Sequence	SEQ ID NO:
5	1	SGRARQ	153
	2	SKSGRS(L)	154
	3	SSRNAD	155
	4	TARLRG	156
10	5	TARSDN	157
	6	TSRMGT	158
	7	TSRQAQ	159
	8	TTRRNK	160
	9	TTSRRS	161
15	10	WSGRSG	162
	11	AIKRSA	163
	12	(G)GRRGNR	164
	13	(G)GRSVNN	165
	14	HTRRMK	166
20	15	ISTARM(L)	167
	16	(S G)KAADV T	168
	17	KKRTND	169
	18	KMSARI(L)	170
	19	(G)KRRDVA	171
25	20	(G)KRVSKN	172
	21	(S G)KSADAA	173
	22	(S G)RAAAM	174
	23	(S G)RAGNIR	175
	24	(S G)RAHRDN	176
30	25	(S G)RARD DR	177
	26	(S G)RARHM	178
	27	(S G)RARS PR	179
	28	(S G)RAVGHQ	180
	29	(S G)RAVVDS	181
35	30	(S G)RGGKGP	182
	31	(S G)RGRSAV	183
	32	(S G)RGVDMN	184
	33	(S G)RGVKMH	185
	34	(S G)RHRSDI	186
40	35	(S G)RKGQGG	187
	36	(S G)RKLHMN	188
	37	(S G)RKMDMG	189
	38	(S G)RKMDRS	190
	39	(S G)RKMRMG	191
45	40	(S G)RKNQ RV	192
	41	(S G)RKQRDS	193
	42	(S G)RKRVGA	194
	43	(S G)RKSKVV	195
	44	(S G)RKSTSS	196
50	45	(S G)RKVGSL	197
	46	(S G)RKASLS	37

Table 6 (continued). Amino acid sequences of the hexapeptide in 89 isolated substrate phage clones.

	Clone Number	Amino acid Sequence	SEQ ID NO:
5	47	(S G)R K V P G S	198
	48	(S G)R K W I S G	199
	49	(S G)R L A T K A	200
	50	(S G)R M R K N D	201
10	51	(S G)R N A Q V R	34
	52	(S G)R N A V E P	202
	53	(S G)R N D R L N	203
	54	(S G)R N G K S R	204
	55	(S G)R N M P L L	205
15	56	(S G)R N T G S H	206
	57	(S G)R R M T M G	207
	58	(S G)R R R L N M	208
	59	(S G)R R T L D F	209
	60	(S G)R R A V S N	38
20	61	(S G)R S A K V D	36
	62	(S G)R S A N A I	33
	63	(S G)R S A T R D	35
	64	(S G)R S A V V K	39
	65	(S G)R S D Q F L	210
25	66	(S G)R S D N P N	211
	67	(S G)R S E R S L	212
	68	(S G)R S G D P G	213
	69	(S G)R S G N T T	214
	70	(S G)R S G N M G	215
30	71	(S G)R S N G V G	216
	72	(S G)R S P D G M	217
	73	(S G)R S R R L P	218
	74	(S G)R S R V T S	219
	75	(S G)R S S H S S	220
35	76	(S G)R S S Q A A	221
	77	(S G)R S S S S H	40
	78	(S G)R S S S T V	222
	79	(S G)R S T D L G	223
	80	(S G)R S T N V E	224
40	81	(S G)R S T R H K	225
	82	(S G)R S Y T N S	226
	83	(S G)R T S P S T	227
	84	(S G)R T S V N L	228
	85	S K R A S I	229
45	86	S Q T C V R(L V)	230
	87	T E R R V R(L V)	231
	88	T Q R S T G	232
	89	T R R D R I	233
	90	V A R M Y K	234
50	91	V S R R N M	235

Kinetic analysis of the cleavage of peptides containing sequences present in selected substrate phage.

Four peptides containing amino acid sequences present in the randomized hexamer region of the most labile phage were chosen for detailed kinetic analysis (Table 7) and compared to hydrolysis of a control peptide (I) containing the P3-P4' sequence of plasminogen, a series of residues which fall within a disulfide-linked loop in the native protein. All four of the selected peptides were substantially improved substrates for u-PA, by factors of 840 - 5300, compared with the control, plasminogen peptide (Table 7). These increases in catalytic efficiency were mediated primarily by increases in k_{cat} , suggesting that optimized subsite interactions served to lower the energy of the transition state rather than the ground state. For example, compared with that of control peptide (I), the K_m for cleavage of the most labile, selected peptide (II) was reduced by a factor of 5.6. However, the k_{cat} was increased by a factor of more than 940. In addition, peptide substrates that interacted optimally with the primary subsites of u-PA were selective for cleavage by u-PA relative to t-PA. The four selected peptides (II - V), for example, were cleaved 16-89 times more efficiently by u-PA than by t-PA, and improvements in both K_m and k_{cat} contributed to the preferential hydrolysis by u-PA.

Table 7. Comparison of k_{cat} , and K_m , and k_{cat}/K_m for the hydrolysis by t-PA or u-PA of peptides selected for preferential cleavage by u-PA

Substrate '(Pn..P3,P2,P1,tP1',P2',P3'..Pn)	u-PA			t-PA			u-PA:t-PA Selectivity	
	SEQ ID NO:	k_{cat} s ⁻¹	K_m (μ M)	k_{cat}/K_m (M ⁻¹ s ⁻¹)	k_{cat} s ⁻¹	K_m (μ M)		k_{cat}/K_m (M ⁻¹ s ⁻¹)
Native cleavage sequence from Plasminogen								
(I) KKSPGR↓VVGGSVAH	1	0.003	3400	0.88	0.0043	15000	0.29	3.0
u-PA selective peptides								
(II) LGGSGR↓SANAILE	11	2.83	603	4700	0.305	4080	75	63
(III) LGGSGR↓NAQVRLE	12	3.69	1160	3200	0.255	7000	36	89
(IV) LGGSGR↓SATRDLE	13	0.54	733	740	0.068	1500	45	16
(V) LGGSGR↓KASLSLE	14	1.14	1130	1010	0.168	5100	33	31
Minimized, u-PA selective peptides								
(VI) SGR↓S	15	2.3	2100	1100	5.0	15000	330	3.3
(VII) SGR↓SA	16	3.7	3100	1200	2.4	40000	60	20
(VIII) SGK↓S	17	1.22	7900	154	0.19	28000	6.8	23
(IX) GSGK↓S	18	0.82	4250	193	0.07	44000	1.6	121
Variants of u-PA selective peptides								
(X) LGGYGR↓SANAILE	236	0.7	2200	318	3.29	1850	1800	0.018
(XI) LGGRGR↓SANAILE	237	0.08	1200	67	0.85	2400	350	0.019
(XII) LGQRGR↓SANAILE	238	0.068	1500	45	2.55	3000	850	0.005

'Positional nomenclature of subsite residues. Arrows denote the position of peptide bond hydrolysis. The peptide bond is cleaved between P1 and P1'. The error in these determinations was 4-22%.

Minimization of the Selective Peptide Substrates.

The kinetic analysis described above was performed using substrate peptides that were 14 amino acids in length. To confirm that the specificity observed was inherent in the selected hexapeptide sequences, the kinetics of cleavage of short peptides containing only sequences found within selected hexapeptide sequences was examined. Pentapeptide VII, for example, was cleaved by u-PA with a catalytic efficiency of $1200 \text{ M}^{-1}\text{s}^{-1}$ and exhibited a u-PA/t-PA selectivity of 20. The behavior of pentamer VII in these assays, therefore, was very similar to that of peptide IV, a 14-mer that contains the same P3-P2' sequence as the pentamer. These observations indicate that appropriate occupancy of the P3-P2' subsites alone can create selective substrates for u-PA.

Differences at position 190 (chymotrypsin numbering system) between u-PA and t-PA suggest that u-PA may exhibit decreased discrimination between arginine and lysine at the P1 position of a substrate compared with t-PA. Consistent with this hypothesis and by contrast to the selected t-PA substrate library, the u-PA library did include members that contained a P1 lysine. This observation suggested that the u-PA/t-PA selectivity of a peptide substrate should be enhanced by placement of lysine in the P1 position although this increased selectivity was likely to be accompanied by decreased reactivity toward u-PA. To test this hypothesis we analyzed hydrolysis of a variant of u-PA selective peptide (VI) that contained a P1 lysine (peptide VIII). The P1 lysine mutation decreased the catalytic efficiency for cleavage of this peptide by a factor of 49 for t-PA and by a factor of 7 for u-PA. As predicted, then, the P1 lysine mutation did enhance the u-PA/t-PA selectivity of the peptide substrate by a factor of approximately 7. It is not surprising, therefore, that the most selective u-PA substrate, peptide IX which is cleaved approximately 121 times more efficiently by u-PA than by t-PA, is derived from the randomized hexamer region of a substrate phage that contained a P1 lysine.

Importance of P3 and P4 for discrimination between u-PA and t-PA.

Recent investigations that explored optimal subsite occupancy for substrates of t-PA suggested that the P3 residue was the primary determinant of

- 37 -

the ability of a substrate to discriminate between t-PA and u-PA and that this selectivity could be enhanced modestly by appropriate occupancy of P4. These suggestions were based on evidence obtained from a statistical analysis of phage selected using a substrate subtraction protocol rather than by a kinetic analysis of peptide substrates. Consequently, to test these hypotheses, we synthesized variants of the most labile u-PA selective substrate (peptide II) that contained mutations in the P3 and/or P4 positions and analyzed the hydrolysis of these peptides by u-PA and t-PA. In peptide X the P3 Serine of peptide II was replaced by a tyrosine, and in peptide XI the P3 serine was replaced by arginine. As expected, these mutations substantially decreased the u-PA/t-PA selectivity of the peptide by factors of 330 or 360, respectively, and actually converted the peptide into a t-PA selective substrate. Moreover, mutation of both the P3 serine and P4 glycine of the most labile u-PA substrate to arginine and glutamine, respectively (peptide XII), decreased the u-PA/t-PA selectivity by a factor of 1200. These data confirm the proposed status of the P3 and P4 residues as specificity determinants for substrates of t-PA and u-PA and suggest a particularly prominent role of the P3 residue in this capacity.

EXAMPLE 4:

Design and Characterization of a

Variant of PAI-1 That is Selective for u-PA.

Analysis of the selected peptide substrates identified in Example 3 indicated that the primary sequence SGRSA, from positions P3 to P2', represented an optimal subsite occupancy for substrates of u-PA. This information was to design a variant of plasminogen activator inhibitor type 1 (PAI-1), the primary physiological inhibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 times more rapidly than it inhibited t-PA.

Specific inhibitors of u-PA were designed using the procedure described in Example 2 by making variants of the PAI-1. Oligonucleotide directed, site specific mutagenesis was used as described in Example 2 to construct a variant of PAI-1 that contained the primary sequence found in the peptide substrate that was most selective for u-PA, GSGKS, from the P4 - P1'

position of the reactive center loop. The mutagenic oligonucleotide had the sequence

5'-CCACAGCTGTCATAGGCAGCGGCAAAAGCGCCCCCGAGGAGATC-3'.

Following mutagenesis, single-stranded DNA corresponding
 5 to the entire 300-bp Sall-BamHI fragment was fully sequenced to ensure the
 presence of the desired mutations and the absence of any additional mutations. The
 300-bp Sall-BamHI dsDNA fragment from the mutated, replicative form DNA
 was used to replace the corresponding fragment in pPAIST7HS to yield a
 full-length cDNA encoding PAI-1/UK1, which contained the amino acid sequence
 10 GSGKSA from the P4 to P2' positions of the reactive center loop.

Kinetic analysis indicated that the PAI-1 variant inhibited u-PA
 approximately 70 times more rapidly than it inhibited t-PA with second order rate
 constants for inhibition of u-PA and t-PA of $6.2 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ and $9 \times 10^4 \text{ M}^{-1}\text{s}^{-1}$,
 respectively. By contrast, wild type PAI-1 inhibits u-PA and t-PA with second
 15 order rate constants of $1.9 \times 10^7 \text{ M}^{-1}\text{s}^{-1}$ and $1.8 \times 10^6 \text{ M}^{-1}\text{s}^{-1}$ respectively. As
 anticipated, therefore, the mutated serpin possessed a u-PA/t-PA selectivity that
 was approximately 7-fold greater than that of wild type PAI-1. Moreover, the
 70-fold selectivity of the PAI-1 variant is consistent with the value of 120
 observed for hydrolysis of the corresponding peptide substrate by the two
 20 enzymes (Tables 7 and 8).

Table 8:
Second order rate constants for inhibition of t-PA or u-PA
by wild type PAI-1 and variant PAI-1/UK1

Inhibitor	SEQ ID NO:	Primary Sequence of reactive center loop (P4-P2')	Rate constant toward u-PA $\text{M}^{-1}\text{s}^{-1}$	Rate constant toward t-PA $\text{M}^{-1}\text{s}^{-1}$	t-PA/u-PA Selectivity
25 Wild type PAI-1	149	VSAR↓MA	1.9×10^7	1.8×10^6	11
PAI-1/UK1	239	GSGK↓SA	6.2×10^6	9.0×10^4	69

Other embodiments of the present invention will be apparent to
 those skilled in the arts of protein engineering or rational drug design.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Madison, Edwin L.
Ke, Song-hua
- (ii) TITLE OF INVENTION: USE OF SUBSTRATE SUBTRACTION LIBRARIES
TO DISTINGUISH ENZYME SPECIFICITIES
- (iii) NUMBER OF SEQUENCES:
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Olson & Hierl, Ltd.
 - (B) STREET: 20 North Wacker Drive, 36th Floor
 - (C) CITY: Chicago
 - (D) STATE: IL
 - (E) COUNTRY: US
 - (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: WordPerfect 5.1 (ASCII File)
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE: 10-JUN-1997
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/019,495
 - (B) FILING DATE: 10-JUN-1996
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Olson, Arne M
 - (B) REGISTRATION NUMBER: 30,203
 - (C) REFERENCE/DOCKET NUMBER: TSRI543.1PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 312-580-1180
 - (B) TELEFAX: 312-580-1189

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Lys Lys Ser Pro Gly Arg Val Val Gly Gly Ser Val Ala His 14
1 5 10

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu Gly Gly Ser Gly Gln Arg Gly Arg Lys Ala Leu Glu 13
1 5 10

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Leu Gly Gly Ser Gly Glu Arg Ala Arg Gly Ala Leu Glu 13
1 5 10

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Leu Gly Gly Ser Gly His Tyr Gly Arg Ser Gly Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Tyr Gly Arg Ser
1

4

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Arg Gly Arg Lys
1

4

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Phe Arg Gly Arg Lys
1 5

5

- (2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Leu Gly Gly Tyr Gly Arg Ser Ala Asn Ala Ile Leu Glu
1 5 10

13

- (2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Leu Gly Gly Arg Gly Arg Ser Ala Asn Ala Ile Leu Glu
1 5 10

13

- (2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 13 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- 43 -

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Leu Gly Gln Arg Gly Arg Ser Ala Asn Ala Ile Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Leu Gly Gly Ser Gly Arg Ser Ala Asn Ala Ile Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Leu Gly Gly Ser Gly Arg Asn Ala Gln Val Arg Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Leu Gly Gly Ser Gly Arg Ser Ala Thr Arg Asp Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Leu Gly Gly Ser Gly Arg Lys Ala Ser Leu Ser Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 4 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Ser Gly Arg Ser
1

4

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

Ser Gly Arg Ser Ala
1 5

5

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 4 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Ser Gly Lys Ser
1

4

(2) INFORMATION FOR SEQ ID NO:18

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

Gly Ser Gly Lys Ser
1 5

5

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

- 46 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

Ala Leu Arg Arg Gly Asp

1

5

6

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

Asp Tyr Arg Gly Arg Met Leu

1

5

7

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

Glu Arg Ala Arg Gly Ala

1

5

6

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

- 47 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Glu Arg Leu Arg Lys Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

Phe Gly Arg His Ala Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

Phe Leu Pro Arg Thr Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:25:

- 48 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Phe Arg Gly Arg Ala Ala
1 5

6

- (2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

His Arg Met Arg Met Gly
1 5

6

- (2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

His Tyr Gly Arg Ser Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

Ile Met Arg Arg Gly Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

Ile Thr Tyr Gly Arg Arg Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

Lys Phe Thr Arg Ser Gly

6

- 50 -

1 5

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

Leu Ile Pro Arg Arg Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

Met Thr Arg Lys Arg Met Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

- 51 -

Asn Phe Ala Arg Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

Asn His Leu Arg Lys Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

Asn Val Gly Arg Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

Asn Val Ser Arg Arg Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

Pro Ile Ser Arg Arg Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:38:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

Pro Val Gly Arg Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:

- 53 -

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Gln Arg Gly Arg Lys Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Arg Leu Leu Arg Ser Val
1 5

6

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Ser Phe Gly Arg Arg His
1 5

6

(2) INFORMATION FOR SEQ ID NO:42:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 54 -

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Ser Leu Arg Gly Arg Ser Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:

Thr Val Leu Arg Arg Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:

Val Ala Arg Arg Val Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

- 55 -

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:

Val Ile Ala Arg Ser Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:46:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

Val Asn Thr Lys Ser Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

Val Arg Ala Arg Gly Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:48:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 56 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:48:

Val Arg Arg Gly Arg Ser Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:49:

Val Arg Arg Arg Gly Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:50:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:

Thr Arg Val Arg Ala Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:51:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

- 57 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51:

Ser Gly Arg Ser Ala Asn Ala Ile
1 5

8

(2) INFORMATION FOR SEQ ID NO:52:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52:

Ser Gly Arg Asn Ala Gln Val Arg
1 5

8

(2) INFORMATION FOR SEQ ID NO:53:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:

Ser Gly Arg Ser Ala Thr Arg Asp
1 5

8

(2) INFORMATION FOR SEQ ID NO:54:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

- 58 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:54:

Ser Gly Arg Ser Ala Lys Val Asp
1 5

8

(2) INFORMATION FOR SEQ ID NO:55:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

Ser Gly Arg Lys Ala Ser Leu Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:56:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:56:

Ser Gly Arg Arg Ala Val Ser Asn
1 5

8

(2) INFORMATION FOR SEQ ID NO:57:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

- 59 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:57:

Ser Gly Arg Ser Ala Val Val Lys
1 5

8

(2) INFORMATION FOR SEQ ID NO:58:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:58:

Ser Gly Arg Ser Ala Val Val Lys
1 5

8

(2) INFORMATION FOR SEQ ID NO:59:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:59:

Ala Ile Lys Arg Ser Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:60:

- 60 -

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: not relevant
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:60:

Gly Arg Arg Gly Asn Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:61:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: not relevant
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

Gly Arg Ser Val Asn Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:62:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 6 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: not relevant
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:62:

His Thr Arg Arg Met Lys
1 5

6

- 61 -

(2) INFORMATION FOR SEQ ID NO:63:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:63:

Ile Ser Thr Ala Arg Met
1 5

6

(2) INFORMATION FOR SEQ ID NO:64:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:

Lys Ala Ala Asp Val Thr
1 5

6

(2) INFORMATION FOR SEQ ID NO:65:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Lys Lys Arg Thr Asn Asp

6

1 5

(2) INFORMATION FOR SEQ ID NO:66:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

Lys Met Ser Ala Arg Ile
1 5

6

(2) INFORMATION FOR SEQ ID NO:67:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:67:

Lys Arg Arg Asp Val Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

Lys Arg Val Ser Lys Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:69:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

Lys Ser Ala Asp Ala Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:70:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:70:

Arg Ala Ala Ala Met Val
1 5

6

(2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

Arg Ala Gly Asn Ile Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:72:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:

Arg Ala His Arg Asp Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:73:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:73:

Arg Ala Arg Asp Asp Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:74:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- 65 -

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:74:

Arg Ala Arg His Met Val
1 5

6

(2) INFORMATION FOR SEQ ID NO:75:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:75:

Arg Ala Arg Ser Pro Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:76:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:76:

Arg Ala Val Gly His Gln
1 5

6

(2) INFORMATION FOR SEQ ID NO:77:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 66 -

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Arg Ala Val Val Asp Ser
1 5

6

- (2) INFORMATION FOR SEQ ID NO:78:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78:

Arg Gly Gly Lys Gly Pro
1 5

6

- (2) INFORMATION FOR SEQ ID NO:79:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 5 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79:

Arg Gly Arg Ser Ala
1 5

5

- (2) INFORMATION FOR SEQ ID NO:80:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:80:

Arg Gly Val Asp Met Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:81:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:

Arg Gly Val Lys Met His
1 5

6

(2) INFORMATION FOR SEQ ID NO:82:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:

Arg His Arg Ser Asp Ile
1 5

6

(2) INFORMATION FOR SEQ ID NO:83:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:

Arg Lys Gly Gln Gly Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:84:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:

Arg Lys Leu His Met Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:85:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:

Arg Lys Met Asp Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:86:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- 69 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:

Arg Lys Met Asp Arg Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:87:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:

Arg Lys Met Arg Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:88:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:

Arg Lys Asn Gln Arg Val
1 5

6

(2) INFORMATION FOR SEQ ID NO:89:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

- 70 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:

Arg Lys Gln Arg Asp Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:90:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:

Arg Lys Arg Val Gly Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:91:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:

Arg Lys Ser Lys Val Val
1 5

6

(2) INFORMATION FOR SEQ ID NO:92:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

- 71 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:

Arg Lys Ser Thr Ser Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:93:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:

Arg Lys Val Gly Ser Leu
1 5

6

(2) INFORMATION FOR SEQ ID NO:94:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:

Arg Lys Val Pro Gly Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:95:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:

Arg Lys Trp Ile Ser Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:96:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:

Arg Leu Ala Thr Lys Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:97:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:

Arg Met Arg Lys Asn Asp
1 5

6

- 73 -

(2) INFORMATION FOR SEQ ID NO:98:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:

Arg Asn Ala Gln Val Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:99:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:

Arg Asn Ala Val Glu Pro
1 5

6

(2) INFORMATION FOR SEQ ID NO:100:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:

Arg Asn Asp Arg Leu Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:101:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:

Arg Asn Gly Lys Ser Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:102:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:

Arg Asn Met Pro Leu Leu
1 5

6

(2) INFORMATION FOR SEQ ID NO:103:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:

Arg Asn Thr Gly Ser His
1 5

6

(2) INFORMATION FOR SEQ ID NO:104:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:

Arg Arg Met Thr Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:105:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:

Arg Arg Arg Leu Asn Met
1 5

6

(2) INFORMATION FOR SEQ ID NO:106:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:

- 76 -

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:

Arg Arg Thr Leu Asp Phe
1 5

6

(2) INFORMATION FOR SEQ ID NO:107:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:

Arg Ser Ala Lys Val Asp
1 5

6

(2) INFORMATION FOR SEQ ID NO:108:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:

Arg Ser Ala Asn Ala Ile
1 5

6

(2) INFORMATION FOR SEQ ID NO:109:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:109:

Arg Ser Ala Thr Arg Asp
1 5

6

(2) INFORMATION FOR SEQ ID NO:110:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:

Arg Ser Ala Val Val Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:111:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Arg Ser Asp Gln Phe Leu
1 5

6

(2) INFORMATION FOR SEQ ID NO:112:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:112:

Arg Ser Asp Asn Pro Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:113:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

Arg Ser Glu Arg Ser Leu
1 5

6

(2) INFORMATION FOR SEQ ID NO:114:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:114:

Arg Ser Gly Asp Pro Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:115:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:

Arg Ser Gly Asn Thr Thr
1 5

6

(2) INFORMATION FOR SEQ ID NO:116:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:116:

Arg Ser Gly Asn Met Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:117:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:117:

Arg Ser Asn Gly Val Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:118:

Arg Ser Pro Asp Gly Met
1 5

6

(2) INFORMATION FOR SEQ ID NO:119:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:

Arg Ser Arg Arg Leu Pro
1 5

6

(2) INFORMATION FOR SEQ ID NO:120:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:120:

Arg Ser Arg Val Thr Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:121:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

- 81 -

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:121:

Arg Ser Ser His Ser Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:122:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:

Arg Ser Ser Gln Ala Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:123:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:123:

Arg Ser Ser Ser Ser His
1 5

6

(2) INFORMATION FOR SEQ ID NO:124:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

- 82 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:124:

Arg Ser Ser Ser Thr Val
1 5

6

(2) INFORMATION FOR SEQ ID NO:125:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Arg Ser Thr Asp Leu Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:126:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

Arg Ser Thr Asn Val Glu
1 5

6

(2) INFORMATION FOR SEQ ID NO:127:

- 83 -

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Arg Ser Thr Arg His Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:128:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:128:

Arg Ser Tyr Thr Asn Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:129:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:129:

Arg Thr Ser Pro Ser Thr
1 5

6

(2) INFORMATION FOR SEQ ID NO:130:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:130:

Arg Thr Ser Val Asn Leu
1 5

6

(2) INFORMATION FOR SEQ ID NO:131:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:

Ser Gly Arg Ala Arg Gln
1 5

6

(2) INFORMATION FOR SEQ ID NO:132:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:132:

Ser Lys Arg Ala Ser Ile

6

1

5

(2) INFORMATION FOR SEQ ID NO:133:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:133:

Ser Lys Ser Gly Arg Ser

1

5

6

(2) INFORMATION FOR SEQ ID NO:134:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:134:

Ser Gln Thr Cys Val Arg

1

5

6

(2) INFORMATION FOR SEQ ID NO:135:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

Ser Ser Arg Asn Ala Asp
1 5

6

(2) INFORMATION FOR SEQ ID NO:136:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:136:

Thr Ala Arg Leu Arg Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:137:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Thr Ala Arg Ser Asp Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:138:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:138:

Thr Glu Arg Arg Val Arg
1 5

6

(2) INFORMATION FOR SEQ ID NO:139:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

Thr Gln Arg Ser Thr Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:140:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

Thr Arg Arg Asp Arg Ile
1 5

6

(2) INFORMATION FOR SEQ ID NO:141:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:141:

Thr Ser Arg Met Gly Thr
1 5

6

(2) INFORMATION FOR SEQ ID NO:142:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:

Thr Ser Arg Gln Ala Gln
1 5

6

(2) INFORMATION FOR SEQ ID NO:143:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:143:

Thr Thr Arg Arg Asn Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:144:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:144:

Thr Thr Ser Arg Arg Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:145:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:145:

Val Ala Arg Met Tyr Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:146:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:146:

Val Ser Arg Arg Asn Met
1 5

6

(2) INFORMATION FOR SEQ ID NO:147:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:147:

Trp Ser Gly Arg Ser Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:148:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:148:

Arg Ile Ala Arg Arg Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:149:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:149:

Val Ser Ala Arg Met Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:150:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- 91 -

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:150:

Val Arg Ala Arg Met Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:151:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:151:

Gln Ser Ala Arg Met Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:152:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:152:

Gln Arg Ala Arg Met Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:153:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:153:

Ser Gly Arg Ala Arg Gln
1 5

6

(2) INFORMATION FOR SEQ ID NO:154:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:154:

Ser Lys Ser Gly Arg Ser Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:155:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:155:

Ser Ser Arg Asn Ala Asp
1 5

6

(2) INFORMATION FOR SEQ ID NO:156:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 6 amino acids

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:156:

Thr Ala Arg Leu Arg Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:157:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:157:

Thr Ala Arg Ser Asp Asn
1 5

6

(2) INFORMATION FOR SEQ ID NO:158:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 6 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:158:

Thr Ser Arg Met Gly Thr
1 6

6

(2) INFORMATION FOR SEQ ID NO:159:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:159:

Thr Ser Arg Gln Ala Gln
1 5

6

(2) INFORMATION FOR SEQ ID NO:160:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:160:

Thr Thr Arg Arg Asn Lys
1 5

6

(2) INFORMATION FOR SEQ ID NO:161:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:161:

Thr Thr Ser Arg Arg Ser
1 5

6

(2) INFORMATION FOR SEQ ID NO:162:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:162:

Trp Ser Gly Arg Ser Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:163:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:163:

Ala Ile Lys Arg Ser Ala
1 5

6

(2) INFORMATION FOR SEQ ID NO:164:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:164:

Gly Gly Arg Arg Gly Asn Arg

7

1

5

(2) INFORMATION FOR SEQ ID NO:165:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:165:

Gly Gly Arg Ser Val Asn Asn

1

5

7

(2) INFORMATION FOR SEQ ID NO:166:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:166:

His Thr Arg Arg Met Lys

1

5

6

(2) INFORMATION FOR SEQ ID NO:167:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:167:

Ile Ser Thr Ala Arg Met Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:168:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:168:

Ser Gly Lys Ala Ala Asp Val Thr
1 5

8

(2) INFORMATION FOR SEQ ID NO:169:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:169:

Lys Lys Arg Thr Asn Asp
1 5

6

(2) INFORMATION FOR SEQ ID NO:170:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:170:

Lys Met Ser Ala Arg Ile Leu
1 5

7

(2) INFORMATION FOR SEQ ID NO:171:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:171:

Gly Lys Arg Arg Asp Val Ala
1 5

7

(2) INFORMATION FOR SEQ ID NO:172:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:172:

Gly Lys Arg Val Ser Lys Asn
1 5

7

(2) INFORMATION FOR SEQ ID NO:173:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:

- 99 -

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:173:

Ser Gly Lys Ser Ala Asp Ala Ala
1 5

8

(2) INFORMATION FOR SEQ ID NO:174:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:174:

Ser Gly Arg Ala Ala Met
1 5

7

(2) INFORMATION FOR SEQ ID NO:175:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:175:

Ser Gly Arg Ala Gly Asn Ile Arg
1 5

8

(2) INFORMATION FOR SEQ ID NO:176:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:176:

Ser Gly Arg Ala His Arg Asp Asn
1 5

8

(2) INFORMATION FOR SEQ ID NO:177:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:177:

Ser Gly Arg Ala Arg Asp Asp Arg
1 5

8

(2) INFORMATION FOR SEQ ID NO:178:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 7 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:178:

Ser Gly Arg Ala Arg His Met
1 5

7

(2) INFORMATION FOR SEQ ID NO:179:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:179:

Ser Gly Arg Ala Arg Ser Pro Arg
1 5

8

(2) INFORMATION FOR SEQ ID NO:180:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:180:

Ser Gly Arg Ala Val Gly His Gln
1 5

8

(2) INFORMATION FOR SEQ ID NO:181:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:181:

Ser Gly Arg Ala Val Val Asp Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:182:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- 102 -

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:182:

Ser Gly Arg Gly Gly Lys Gly Pro
1 5

8

- (2) INFORMATION FOR SEQ ID NO:183:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:183:

Ser Gly Arg Gly Arg Ser Ala Val
1 5

8

- (2) INFORMATION FOR SEQ ID NO:184:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: peptide
 - (iii) HYPOTHETICAL: NO
 - (iv) ANTI-SENSE: NO
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:184:

Ser Gly Arg Gly Val Asp Met Asn
1 5

8

- (2) INFORMATION FOR SEQ ID NO:185:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:185:

Ser Gly Arg Gly Val Lys Met His
1 5

8

(2) INFORMATION FOR SEQ ID NO:186:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:186:

Ser Gly Arg His Arg Ser Asp Ile
1 5

8

(2) INFORMATION FOR SEQ ID NO:187:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:187:

Ser Gly Arg Lys Gly Gln Gly Gly
1 5

8

(2) INFORMATION FOR SEQ ID NO:188:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:188:

Ser Gly Arg Lys Leu His Met Asn

1

5

8

(2) INFORMATION FOR SEQ ID NO:189:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:189:

Ser Gly Arg Lys Met Asp Met Gly

1

5

8

(2) INFORMATION FOR SEQ ID NO:190:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:190:

Ser Gly Arg Lys Met Asp Arg Ser

1

5

8

(2) INFORMATION FOR SEQ ID NO:191:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

- 105 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:191:

Ser Gly Arg Lys Met Arg Met Gly
1 5

8

(2) INFORMATION FOR SEQ ID NO:192:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:192:

Ser Gly Arg Lys Asn Gln Arg Val
1 5

8

(2) INFORMATION FOR SEQ ID NO:193:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:193:

Ser Gly Arg Lys Gln Arg Asp Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:194:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:194:

Ser Gly Arg Lys Arg Val Gly Ala
1 5

8

(2) INFORMATION FOR SEQ ID NO:195:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:195:

Ser Gly Arg Lys Ser Lys Val Val
1 5

8

(2) INFORMATION FOR SEQ ID NO:196:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:196:

Ser Gly Arg Lys Ser Thr Ser Ser
1 5

8

- 107 -

(2) INFORMATION FOR SEQ ID NO:197:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:197:

Ser Gly Arg Lys Val Gly Ser Leu
1 5

8

(2) INFORMATION FOR SEQ ID NO:198:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:198:

Ser Gly Arg Lys Val Pro Gly Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:199:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:199:

Ser Gly Arg Lys Trp Ile Ser Gly

8

1

5

(2) INFORMATION FOR SEQ ID NO:200:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:200:

Ser Gly Arg Leu Ala Thr Lys Ala

1

5

8

(2) INFORMATION FOR SEQ ID NO:201:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:201:

Ser Gly Arg Met Arg Lys Asn Asp

1

5

8

(2) INFORMATION FOR SEQ ID NO:202:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:202:

Ser Gly Arg Asn Ala Val Glu Pro
1 5

8

(2) INFORMATION FOR SEQ ID NO:203:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:203:

Ser Gly Arg Asn Asp Arg Leu Asn
1 5

8

(2) INFORMATION FOR SEQ ID NO:204:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:204:

Ser Gly Arg Asn Gly Lys Ser Arg
1 5

8

(2) INFORMATION FOR SEQ ID NO:205:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- 110 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:205:

Ser Gly Arg Asn Met Pro Leu Leu
1 5

8

(2) INFORMATION FOR SEQ ID NO:206:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:206:

Ser Gly Arg Asn Thr Gly Ser His
1 5

8

(2) INFORMATION FOR SEQ ID NO:207:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:207:

Ser Gly Arg Arg Met Thr Met Gly
1 5

8

(2) INFORMATION FOR SEQ ID NO:208:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:

- 111 -

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:208:

Ser Gly Arg Arg Arg Leu Asn Met
1 5

8

(2) INFORMATION FOR SEQ ID NO:209:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:209:

Ser Gly Arg Arg Thr Leu Asp Phe
1 5

8

(2) INFORMATION FOR SEQ ID NO:210:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:210:

Ser Gly Arg Ser Asp Gln Phe Leu
1 5

8

(2) INFORMATION FOR SEQ ID NO:211:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- 112 -

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:211:

Ser Gly Arg Ser Asp Asn Pro Asn
1 5

8

- (2) INFORMATION FOR SEQ ID NO:212:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:212:

Ser Gly Arg Ser Glu Arg Ser Leu
1 5

8

- (2) INFORMATION FOR SEQ ID NO:213:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:

Ser Gly Arg Ser Gly Asp Pro Gly
1 5

8

- (2) INFORMATION FOR SEQ ID NO:214:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: not relevant
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- 113 -

- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:

Ser Gly Arg Ser Gly Asn Thr Thr
1 5

8

(2) INFORMATION FOR SEQ ID NO:215:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:

Ser Gly Arg Ser Gly Asn Met Gly
1 5

8

(2) INFORMATION FOR SEQ ID NO:216:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

Ser Gly Arg Ser Asn Gly Val Gly
1 5

8

(2) INFORMATION FOR SEQ ID NO:217:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide

- 114 -

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

Ser Gly Arg Ser Pro Asp Gly Met
1 5

8

(2) INFORMATION FOR SEQ ID NO:218:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

Ser Gly Arg Ser Arg Arg Leu Pro
1 5

8

(2) INFORMATION FOR SEQ ID NO:219:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:219:

Ser Gly Arg Ser Arg Val Thr Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:220:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:220:

Ser Gly Arg Ser Ser His Ser Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:221:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:221:

Ser Gly Arg Ser Ser Gln Ala Ala
1 5

8

(2) INFORMATION FOR SEQ ID NO:222:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:222:

Ser Gly Arg Ser Ser Ser Thr Val
1 5

8

(2) INFORMATION FOR SEQ ID NO:223:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:223:

Ser Gly Arg Ser Thr Asp Leu Gly
1 5

8

(2) INFORMATION FOR SEQ ID NO:224:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:224:

Ser Gly Arg Ser Thr Asn Val Glu
1 5

8

(2) INFORMATION FOR SEQ ID NO:225:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: not relevant

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:225:

Ser Gly Arg Ser Thr Arg His Lys
1 5

8

(2) INFORMATION FOR SEQ ID NO:226:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 8 amino acids

- 117 -

- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:226:

Ser Gly Arg Ser Tyr Thr Asn Ser
1 5

8

(2) INFORMATION FOR SEQ ID NO:227:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:227:

Ser Gly Arg Thr Ser Pro Ser Thr
1 5

8

(2) INFORMATION FOR SEQ ID NO:228:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: not relevant
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:228:

Ser Gly Arg Thr Ser Val Asn Leu
1 5

8

(2) INFORMATION FOR SEQ ID NO:229:

- 118 -

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:229:

Ser Lys Arg Ala Ser Ile
1 5

6

- (2) INFORMATION FOR SEQ ID NO:230:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:230:

Ser Gln Thr Cys Val Arg Leu Val
1 5

8

- (2) INFORMATION FOR SEQ ID NO:231:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 8 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:231:

Thr Glu Arg Arg Val Arg Leu Val
1 5

8

(2) INFORMATION FOR SEQ ID NO:232:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:232:

Thr Gln Arg Ser Thr Gly
1 5

6

(2) INFORMATION FOR SEQ ID NO:233:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:233:

Thr Arg Arg Asp Arg Ile
1 5

6

(2) INFORMATION FOR SEQ ID NO:234:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:234:

Val Ala Arg Met Thr Lys

6

1

5

(2) INFORMATION FOR SEQ ID NO:235:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:235:

Val Ser Arg Arg Asn Met

1

5

6

(2) INFORMATION FOR SEQ ID NO:236:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:236:

Leu Gly Gly Tyr Gly Arg Ser Ala Asn Ala Ile Leu Glu

1

5

10

13

(2) INFORMATION FOR SEQ ID NO:237:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:237:

- 121 -

Leu Gly Gly Arg Gly Arg Ser Ala Asn Ala Ile Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:238:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:238:

Leu Gly Gln Arg Gly Arg Ser Ala Asn Ala Ile Leu Glu
1 5 10

13

(2) INFORMATION FOR SEQ ID NO:239:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 6 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: not relevant
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: peptide

- (iii) HYPOTHETICAL: NO

- (iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:239:

Gly Ser Gly Lys Ser Ala
1 5

6

WE CLAIM:

1. A substrate subtraction library for the identification of peptide substrates selective between a first enzyme and a second enzyme, comprising a collection of different peptides, the library substantially lacking peptides that are effective substrates for the first enzyme.
2. The composition of claim 1 wherein the identified substrates have a selectivity for the second enzyme over the first enzyme of at least 10 fold.
3. The composition of claim 1 wherein the identified substrates have a selectivity for the second enzyme over the first enzyme of at least 50 fold.
4. The composition of claim 1 wherein the peptides in the combinatorial library have a k_{cat}/K_m ratio of less than about $500 \text{ M}^{-1}\text{s}^{-1}$.
5. The composition of claim 1 wherein the peptides in the combinatorial library have a k_{cat}/K_m ratio of less than about $100 \text{ M}^{-1}\text{s}^{-1}$.
6. A method of identifying peptide substrates selective between a first enzyme and a second enzyme, comprising the steps of:
 - 1) providing a combinatorial library comprising components that display different peptides;
 - 2) contacting the combinatorial library with the first enzyme to permit the first enzyme to modify some of the components of the combinatorial library;
 - 3) separation of the portion of the library that is substantially unmodified by the first enzyme from the portion that is modified by the first enzyme;
 - 4) then:
 - a) contacting the modified portion with the second enzyme; or
 - b) contacting the unmodified portion with the second enzyme;
 - 5) and identifying at least some of the components of the combinatorial library that are modified by one enzyme but substantially

unmodified by the other enzyme.

7. The method of claim 6 wherein the step of identifying at least some of the components of the combinatorial library that are modified by the one enzyme but not the other includes determining the amino acid sequence of at least one of the displayed peptides.

8. The method of claim 6 wherein the provided combinatorial library has been pre-processed by the steps of contacting the library with the second enzyme and selecting for the provided library components which are modified by the second enzyme.

9. The method of claim 6 wherein the first enzyme and the second enzyme are both proteases.

10. The method of claim 6 wherein the first enzyme and the second enzyme are both kinases.

11. The method of claim 6 wherein the first enzyme and the second enzyme are both phosphatases.

12. The method of claim 6 wherein the combinatorial library is a bacteriophage display library.

13. A compound comprising the amino acid sequence of claim 7.

14. The compound of claim 13, wherein the compound inhibits the activity of the one enzyme.

15. The compound of claim 13, wherein the compound inhibits the activity of the one enzyme and does not substantially inhibit the activity of the other enzyme.

16. A compound comprising the amino acid sequence determined by the method of claim 7.

17. The compound of claim 16, wherein the compound inhibits the activity of the one enzyme.

18. The compound of claim 16, wherein the compound inhibits the activity of the one enzyme and does not substantially inhibit the activity of the

other enzyme.

19. A method of identifying peptide substrates selective between a first enzyme and a second enzyme, comprising the steps of:

providing a combinatorial library comprising different peptides;

5 contacting at least a first portion of the combinatorial library with the first enzyme to permit the first enzyme to modify some of the peptides of the combinatorial library;

 contacting at least a second portion of the combinatorial library with the second enzyme to permit the second enzyme to modify some of the peptides of the combinatorial library, wherein the second portion includes at least
10 some of the same peptides as the first portion; and

 identifying at least one of the peptides of the combinatorial library that are modified by one enzyme but are substantially unmodified by the other enzyme.

15 20. The method of claim 19 wherein the step of identifying at least one peptide includes determining the sequence of that peptide.

21. The method of claim 19 wherein the combinatorial library is first contacted with the first enzyme to create an intermediate combinatorial library which is then contacted with the second enzyme.

20 22. A compound produced by the process of identifying peptide substrates selective between a first enzyme and a second enzyme, comprising the steps of:

providing a combinatorial library comprising different peptides;

 contacting at least a first portion of the combinatorial library with
25 the first enzyme to permit the first enzyme to modify some of the peptides of the combinatorial library;

 contacting at least a second portion of the combinatorial library with the second enzyme to permit the second enzyme to modify some of the peptides of the combinatorial library, wherein the second portion includes at least
30 some of the same peptides as the first portion;

identifying at least one of the peptides of the combinatorial library that are modified by one enzyme but substantially unmodified by the other enzyme; and

5 producing a polypeptide having an amino acid sequence corresponding to the peptide identified.

23. The compound of claim 22, wherein the compound inhibits the activity of the one enzyme.

24. The compound of claim 22, wherein the compound inhibits the activity of the one enzyme and does not substantially inhibit the activity of the
10 other enzyme.

25. A polypeptide for use as an enzyme inhibitor comprising an amino acid sequence chosen from the group consisting of SEQ ID NO:2 to SEQ ID NO:148 and SEQ ID NO:150 to SEQ ID NO:239.

26. The polypeptide of claim 25 wherein the amino acid
15 sequence is selected from the group consisting of SEQ ID NO:2 to SEQ ID NO:10.

27. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:11 to SEQ ID NO:20.

28. The polypeptide of claim 25 wherein the amino acid
20 sequence is selected from the group consisting of SEQ ID NO:21 to SEQ ID NO:30.

29. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:141 to SEQ ID
25 NO:148.

30. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:150 to SEQ ID NO:160.

31. The polypeptide of claim 25 wherein the amino acid
30 sequence is selected from the group consisting of SEQ ID NO:161 to SEQ ID

NO:170.

32. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:171 to SEQ ID NO:180.

5 33. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:181 to SEQ ID NO:190.

34. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:191 to SEQ ID
10 NO:200.

35. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:201 to SEQ ID NO:210.

36. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:211 to SEQ ID
15 NO:220.

37. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:221 to SEQ ID NO:230.

20 38. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:231 to SEQ ID NO:239.

39. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:5, SEQ ID NO:6
25 and SEQ ID NO:7.

40. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9 and SEQ ID NO:10.

41. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:11, SEQ ID
30

NO:12, SEQ ID NO:13 and SEQ ID NO:14.

42. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18.

5 43. The polypeptide of claim 25 wherein the amino acid sequence is selected from the group consisting of SEQ ID NO:150, SEQ ID NO:151, SEQ ID NO:152 and SEQ ID NO:239.

44. A recombinant DNA vector comprising DNA encoding a protease inhibitor including the amino acid sequence determined by the method of
10 claim 7.

45. A prokaryotic cell containing the vector of claim 44.

46. A eukaryotic cell containing the vector of claim 44.

47. An antibody immunoreactive with at least one of the peptides identified in claim 19.

15 48. An antibody for the affinity purification of recombinant peptides that is immunoreactive with a peptide having the amino acid sequence of claim 7.

49. An antibody for the identification of naturally occurring protease inhibitors that is immunoreactive with at least one of the peptides
20 identified in claim 19.

50. A diagnostic assay distinguishing between active and latent forms of protease inhibitors comprising an antibody that is immunoreactive with a peptide having the amino acid sequence of claim 7.

25 51. An antibody immunoreactive with the compound of claim 13.

52. An antibody for the affinity purification of recombinant peptides that is immunoreactive with the compound of claim 13.

53. An antibody for the identification of naturally occurring protease inhibitors that is immunoreactive with the compound of claim 16.


30 54. A diagnostic assay distinguishing between active and latent

forms of protease inhibitors comprising an antibody that is immunoreactive with the compound of claim 16.

- 5 55. A method of treating a patient having a serpin deficiency comprising administering a physiologically effective amount of the peptide of claim 7 to the patient.

 56. A method of treating a patient having a disorder of serine proteases comprising administering a physiologically effective amount of the peptide of claim 22.

1/4



2 / 4




FIG. 2

3/4




FIG. 3

4/4




FIG. 4

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US97/09760

A. CLASSIFICATION OF SUBJECT MATTER IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/252.3, 320.1, 325; 530/33, 326, 330, 387.1; 536/23.1; 935/22 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	LAM, K.S. Application of combinatorial library methods in cancer research and drug discovery. Anti-Cancer Drug Design. January 1997, Vol. 12, pages 145-167, see entire document.	1-12 and 19-21
A	LAM et al. A new type of synthetic peptide library for identifying ligand-binding activity. Nature. 07 November 1991, Vol. 354, pages 82-84; see entire document.	1-12 and 19-21
A	HOUGHTEN et al. Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature. 07 November 1991, Vol. 354, pages 84-86, see entire document.	1-12 and 19-21
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family	
Date of the actual completion of the international search 22 OCTOBER 1997		Date of mailing of the international search report 19 NOV 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer EINAR STOLE Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09760

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BRONNER et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. <i>Nature</i> . 17 March 1994, Vol. 368, pages 258-261, especially 259.	25 and 30
X	BATES et al. Characterization of a cryptic plasmid from <i>Lactobacillus plantarum</i> . <i>Gene</i> . 1989, Vol. 85, pages 253-258, especially 255 and 256.	25 and 38
X	RAMSEIER et al. Discovery and sequence analysis of bacterial genes involved in the biogenesis of c-type cytochromes. <i>J. Biol. Chem.</i> 25 April 1991, Vol. 266, No. 12, pages 7793-7803, especially 7796.	25 and 42
X	HIRATSUKA et al. The complete sequence of the rice (<i>Oryza sativa</i>) chloroplast genome: Intermolecular recombination between distinct tRNA genes accounts for a major plastid DNA inversion during the evolution of the cereals. <i>Molecular and General Genetics</i> . June 1989, Vol. 217, No. 2/3, pages 185-194, especially 191.	25 and 42
X	DUNCAN et al. Alternative splicing of STY, a nuclear dual specificity kinase. <i>J. Biol. Chem.</i> 15 September 1995, Vol. 270, No. 37, pages 21524-21531, especially 21526 and 21528.	25 and 42
X	LACOSTE et al. Characterization and cloning of p11, a transrepressor of <i>Drosophila melanogaster</i> retrotransposon 1731. <i>Nucleic Acids Research</i> . December 1995, Vol. 23, No. 24, pages 5073-5079, especially 5076.	25, 26 and 39
X	KURAMOCHI et al. Characterization of murine erythropoietin receptor genes. <i>Journal of Molecular Biology</i> . 05 December 1990, Vol. 216, No. 3, pages 567-575, especially 569 and 571.	25, 30 and 43
X	AKIYAMA et al. An exopolyphosphatase of <i>Escherichia coli</i> : The Enzyme and its ppx Gene in a Polyphosphate Operon. <i>J. Biol. Chem.</i> 05 January 1993, Vol. 268, No. 1, pages 633-639, especially 635.	25, 30 and 43
X	DE GROOT et al. Characterization of type IV pilus genes in plant growth-promoting <i>Pseudomonas putida</i> WCS358. <i>Journal of Bacteriology</i> . February 1994, Vol. 176, No. 3, pages 642-650, especially 646-648.	25, 38 and 43

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/09760

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-49 and 51-53
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☒
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/09760

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 38/00, 38/04; C07H 21/02; C07K 16/00; C12N 1/20, 5/00, 15/00

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/252.3, 320.1, 325; 530/33, 326, 330, 387.1; 536/23.1; 935/22

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

Database: APS, CAS ONLINE, CAPLUS, MEDLINE, REGISTRY

search terms: combinatorial library, peptides, serpins, trypsin, chymotrypsin, protease, peptidase, inhibitors, subtraction library, and combinations thereof.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claim(s) 1-46, drawn to peptide compositions, methods of use thereof, and vectors and transformed host cells encoding peptides.

Group II, claim(s) 47-49 and 51-53, drawn to antibodies.

Group III, claim(s) 50 and 54, drawn to an assay using antibodies.

Group IV, claims 55 and 56, drawn to methods of treatment using peptides.

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of the Group I invention is the method of substrate subtraction using combinatorial peptide libraries, and vectors and cells encoding these peptides, whereas the special technical feature of the Group II invention is specific antibodies against peptides. Since the special technical feature of the Group I invention is not shared with the Group II claims, unity of invention is lacking.

The inventions listed as Groups III and IV are drawn to additional methods of using the antibodies of the Group II invention, and therefore do not share a special technical feature with Group I.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.